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Abstract 
Medication-Assisted Treatment in Criminal Justice Systems: A Qualitative Study on 
Treatment Orientation, Barriers, and Facilitators of Allegheny County Jail 
 
Jose E. Silva Jr., MPH 
 
University of Pittsburgh, 2019 
 
Abstract  
 
Background: Justice-involved populations have high rates of opioid dependency and are at most 
risk for overdose events, especially in the immediate post-release period. Excessive mortality rates 
are largely attributed to these overdose events. Medication-assisted treatment (MAT) has been 
underutilized in the treatment of opiate-dependent criminal justice populations. Consequently, 
health care policies within this sector often fail to provide evidence-based treatment that may 
hinder or disrupt the rehabilitation of detained offenders.  
Purpose: Opioid-related fatal overdoses are a significant public health concern in Allegheny 
County, Pennsylvania, especially among justice-involved populations reentering into society. 
Despite the effectiveness of pharmacological intervention, Allegheny County Jail has limited the 
provision of MAT to expectant mothers. Understanding local jail policy and its implications on 
the general rehabilitation of its returning citizens in the community is important for addressing 
barriers to efficacious treatment, facilitating effective service utilization, and informing policy. 
Methods: To understand Allegheny County Jail’s barriers to facilitating MAT and its related 
treatment implications on the greater community, we examined the perceptions, experiences, and 
knowledge of 15 stakeholders. Semistructured interviews and a survey were used to gather 
qualitative data from a convenience sample of respondents. A qualitative matrix analysis was then 
developed to organize categorical constructs from responses across different groups of 
stakeholders. 
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Results: These findings have a great public health significance as they show how Allegheny 
County can target and mitigate treatment gaps associated with the detoxification of an individual 
in active community recovery. Methadone and buprenorphine should be provided to prevent lapses 
in treatment as well as timely linkage to community-based providers during incarceration. Many 
expressed views consistent with stigmatized beliefs about methadone and buprenorphine, and cited 
the jail administration’s punitive approach to substance abuse treatment. Other major factors 
included the difficulty in treating a transient jail population, associated cost of medication, and 
security concerns with administration and management of a controlled substance. These factors 
were found to negatively impact the provision and continuity of MAT practice in Allegheny 
County. Public health interventions will require criminal justice systems alike to reform policy that 
improves health outcomes of opiate-dependent offenders and reduces their involvement in the 
criminal justice system.  
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1.0 Introduction 
Since the introduction of the opioid analgesic OxyContin in 1995, the rate of prescription 
and non-prescription opioid misuse and its associated health implications, including overdose, has 
progressively increased in the U.S. [1]. In tandem with this epidemic, an unprecedented number 
of people who use drugs, predominantly those eliciting opioid-dependent symptoms, have steadily 
increased in U.S. criminal justice systems [2]. As a result, black-market opioids, heroin, and 
illicitly manufactured fentanyl and its analogues, have significantly contributed to the prevalence 
of opioid use disorders (OUD) among justice-involved populations [3]. Consequently, opioid-
related overdoses are now the leading cause for unintentional injury deaths in the U.S. [4]. Several 
surveillance reports and research find formerly incarcerated adults, who often cycle in and out of 
criminal justice institutions without formal substance use treatment, as the most susceptible to 
mortality risk [5].  
It follows that the underprovision of OUD treatment within penal institutions leads to 
adverse withdrawal symptoms during forced detox, a reduction in opiate tolerance, and subsequent 
elevated risk to overdose and mortality on release [5]. Additionally, released inmates—or returning 
citizens—leave uninsured, without access to health services; this is exacerbated by the high annual 
turnover and reincarceration rates, which are linked with increased spread of infectious diseases 
such as HIV risk behaviors, especially through ‘needle sharing.’ The combination of these 
associated harms and inadequate opioid misuse treatment creates a large-scale public health 
problem, profoundly impacting the health outcomes of returning citizens and their respective 
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communities [6].While psychotherapy has been commonly used to treat substance use disorders, 
particularly cocaine, benzodiazepine, or other acting stimulants, opioid and alcohol use disorders 
have the pharmacological advantage of being treated with U.S. Food and Drug Administration 
(FDA) approved medications, including evidence-based treatment formulations of methadone, 
buprenorphine, and naltrexone [7]. Collectively, these substance use disorder medications are 
interchangeably referred to as medication assisted treatment (MAT), opiate maintenance therapy, 
or pharmacotherapy [7]. Furthermore, pharmacotherapy and psychotherapy’s integrative 
applicability has been found to enhance treatment outcomes among opiate-dependent individuals, 
and is recommended by the World Health Organization (WHO) and the Substance Abuse Mental 
Health Services Administration (SAMHSA) for both general and incarcerated populations [7]. 
Thus, expanding access to OUD treatment for inmates, including the provision of MAT and 
counseling services, advances the constitutional right for medical treatment and offers a unique 
public health opportunity to treat prisoners as patients [8].  
In this study, opioid-related mortality rates and sociodemographic risk factors are reviewed 
from available surveillance reports and research conducted among criminal justice populations. 
Additionally, findings from the most recent literature on the efficacy of MAT implementation 
within criminal justice institutions, domestically and internationally, is examined. Finally, to 
develop a comprehensive understanding of the current state of MAT—its barriers and 
facilitators—within Allegheny County Jail, opioid use disorder treatment services and protocols 
are assessed. To further evaluate Allegheny County Jail’s treatment implications, semi-structured 
qualitative interviews were conducted with community stakeholders who directly admit or provide 
some level of care or service to the formerly incarcerated, specifically returning citizens diagnosed 
with opioid use disorder at risk for relapse and overdose following release. By collecting this 
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information from key informants in Allegheny County, attitudes, barriers, and policies that may 
influence Allegheny County Jail’s use of MAT can be further assessed and translated into 
recommendations for improving substance use treatment for opioid using offenders.  
 
 
 
 
. 
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2.0 Background 
Since 1973, the U.S. imprisonment rate has quadrupled to where U.S. criminal justice 
systems now constitute nearly a quarter of the world’s incarcerated population [9]. Today, the U.S. 
penal system continues to account for not only the largest incarceration rate in the world at just 
over 2.16 million [9], but the highest drug dependence and abuse rates, with National Inmate 
Surveys finding 63% of local jail inmates and 58% of state prisoners meeting medical criteria for 
substance dependence, as reported by the Bureau of Justice Statistics [2]. This is in stark contrast 
to the 8.4% prevalence of substance use disorder (SUD) rates among adults aged 18 or older 
throughout the United States [10].  
Historically, substance use disorders (SUDs) were not viewed as a global health priority, 
especially amidst other chronic and infectious disease ailments; however, sharp increases of 41% 
of all of these associated burdens with mental, substance use, and neurological disorders, between 
1990 and 2010, have raised significant concerns within the healthcare industry [11]. Research has 
indicated that individuals with SUDs have a higher prevalence of medical conditions and disease 
burdens compared to non-SUD individuals, particularly among opioid-dependent users. This is 
further exacerbated by estimates indicating that just over 12% of individuals in need of specialized 
SUD treatment ever receive it [12]. These conditions place this subpopulation at greater risk for 
poor health outcomes, including high morbidity and early mortality [13]. As a consequence, SUD 
treatment underutilization has led to an overrepresentation of drug-dependent individuals in not 
only primary care and trauma center settings [13], but criminal justice institutions [14]. 
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From a medical perspective, this poses a daunting public health risk with prisoners bearing 
the disproportionate burden of carrying and contracting higher rates of infectious diseases, such as 
HIV, STIs, tuberculosis, and hepatitis B and C—in addition to other chronic conditions [6]. 
Previous studies have estimated that a significant percentage of Americans bearing the following 
conditions pass through correctional facilities every year: 30% with hepatitis B virus (HBV); 43% 
with hepatitis C virus (HCV); and 40% with tuberculosis (TB) [14]. The interface between HIV 
and injection-drug users is even more pronounced, especially when considering that about one-
sixth of an estimated 1.1 million individuals living with HIV pass through the criminal justice 
system (CJS) annually [15]. Moreover, heroin injection alone has seen a 63% surge from 2002 to 
2013 [3]. This is particularly alarming given that a significant antecedent to drug injection stems 
from prescription opioid abuse; studies show that 4 in 5 heroin users started by abusing 
prescriptions opioids [16]. This shift in drug use behavior is critical to track when considering that 
death rates were predominately driven by prescription opioids (e.g. OxyContin, Percocet, Vicodin) 
in the early 2000s; now, that rate is 6 times higher and propelled by heroin and illicit fentanyl [3]. 
Because justice-involved individuals are more likely to experience drug dependence, epidemics of 
infectious disease, substance abuse, and incarceration are inextricably intertwined [17].  
Extant literature estimates that approximately 24–36% of all heroin users pass through the 
U.S. penal system every year, with 20% presenting injection-drug using behavior [18]. However, 
a recent nationwide survey found that approximately one-third of individuals with opioid use 
disorder and 40% of heroin users had current or previous criminal justice involvement [19]. Yet, 
less than 5% of individuals who were referred to opioid use disorder treatment ever received it 
within the criminal justice health care system [20], which represents missed opportunities to 
engage them in care. And while criminal justice populations have historically experienced higher 
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burdens of disease and been medically underserved [21], these alarming statistics come at a time 
where rising drug deaths have been eclipsed by opioid-related overdose rates—predominantly by 
the introduction of fentanyl and its analogues in the drug supply market [22]. Compounded by 
concentrated OUD rates, a lack of standardized SUD treatment, and subsequent elevated post-
release mortality rates, criminal justice institutions have become the epicenter of best predicting 
opioid overdoses in the community.  
In the context of community health care, correctional systems have the opportunity to serve 
as public health partners for a high-risk, disenfranchised population that seldom receive adequate 
health care services, if at all [6]. Every year, 3,283 jails will process 10.6 million admissions [23], 
in contrast to 1,821 state and federal prisons that recorded 606,000 admissions in 2016 [24]. 
Therefore, jails—more so than prisons—are uniquely positioned to provide behavioral and health 
intervention services to inmates that are more likely to continue contributing to the local public 
health burdens of a community [6]. For a majority of incarcerated Americans, encountering 
preventive and chronic medical care for the first time will occur within a correctional setting [25], 
with an estimated 40% receiving a chronic medical diagnosis during incarceration [26]. Because 
opioid use disorders have become more concentrated and pervasive throughout American 
correctional settings [27], incarceration events provide the potential for identifying and treating 
adults with opiate-dependent symptoms—especially for those not enrolled in community-based 
treatment at time of booking [28]. In light of the continuity of care, it is imperative for health policy 
officials to ensure inmates receive adequate substance use and linkage services—as drug relapse 
exceeds 85% without proper diagnosis and treatment post-release [17].  
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Furthermore, community reentry service providers, researchers, and policy makers 
emphasize the first three months following release as being the most critical time period to 
reintegrate the returning citizen; if successful community reintegration is not attained in this 
timeframe, it is most likely never to happen [29]. Unfortunately, the narrative of reincarceration 
follows more than 75% of all released inmates [30], with one-third returning to their drug-seeking 
habits within the first two months [31]. For others—specifically opioid-dependent adults—that 
“revolving door” comes to a halt with a fatal overdose.  
2.1 Review of Post-Incarceration Overdose Mortality Risk Factors & Rates 
As opioid use and misuse continues to be a pressing public health risk for vulnerable 
correctional populations, states and counties across the U.S. are starting to take notice of 
overwhelming trends identified through recent overdose surveillance reports and retrospective 
cohort studies. While most research in the area of health policy reform has focused on short-term 
physical health improvements among those incarcerated [32], emerging literature has shown that 
policies and practices need to shift their paradigm of substance use care among opioid-dependent 
offenders. Globally and domestically, the leading mortality indicator among substance abuse 
returning citizens is unintentional drug overdose; the most common drug class being opioids [22], 
especially in the immediate post-release period [33]. Risks may be explained by lapses of MAT 
while incarcerated, poor social support, re-exposure to drug networking environment, and a 
significantly decreased opioid tolerance, all of which exacerbate and contribute to the relapse and 
overdose cycle [33]. Among socioeconomic stressors, lack of health insurance [6], education, 
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income, and unemployment also have significant implications on the growing opioid crisis in the 
U.S. [34]. 
A study conducted in the Washington State Department of Corrections, found that released 
inmates were at a markedly higher risk for drug overdose during the first two weeks of reentry—
with a risk rate of 129 times greater than non-incarcerated state residents [5]. Among all overdose 
cases, 80% were attributed to men who were predominantly non-Hispanic white and younger than 
45 [5]; the majority of incidences involved opiates/sedatives [35]. Their average length of 
incarceration was around one month; however, about one-quarter of the follow-up cohort were 
found to have been incarcerated and released more than once [5]. Other significant risk factors for 
overdose mortality included a positive SUD diagnosis, history of injection-drug use, history of 
panic disorder, and receipt of a psychiatric prescription within 60 days prior to release [35]. Even 
though MAT was not provided during incarceration period, traditional SUD treatment was 
associated with a reduced risk for overdose death and all-cause death groups [35].  
In a Philadelphia Department of Prisons study, death records were obtained and assessed 
from the Pennsylvania Department of Health’s Bureau of Vital Records from 2010 to 2016. Fatal 
overdoses were most prominent in the first week following jail release, with a mortality rate of 
over 2,000 deaths per 100,000 person-years [36]. Of the 33%, or 837, of 2,522 cases succumbing 
to fatal overdose, 72% occurred within the first two weeks of release—a trend not observed among 
all-cause death cases. Fentanyl and heroin were found to be overwhelmingly responsible for the 
majority of overdose decedents [36]. Race and age were strong predictors for overdose specific 
death among men and women, with non-Hispanic individuals between ages of 25 and 34, 
experiencing a 11.23 times higher incidence of overdose than their non-incarcerated counterparts 
of same sociodemographic characteristics [36]. Additionally, higher case incidences of overdose 
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were reported among returning citizens that had been incarcerated for more than a month but less 
than six, with an average stay of 68 days [36]. During the period of this study, only individuals 
receiving community-based MAT at time of arrest were eligible to continue receiving treatment 
while imprisoned—a facilitator towards continuing treatment, but barrier to those in need of 
beginning treatment [36]. Methadone and buprenorphine is now available to all those meeting 
OUD criteria to start while incarcerated [36]. 
Among New York City jails, a study was conducted between 2011 and 2012 that identified 
opioid overdose as the highest cause-of-death marker following release, with 37.3% of case 
fatalities in this cohort occurring within the first 42 days [37]. Deaths from overdose were most 
common among non-Hispanic White men, accounting for nearly 97% of overdoses; the reported 
mean age was 41 [37]. The median incarceration period before release was 43 days for opioid-
related fatal overdose cases [37]. Of all opioid-related fatality cases, 77% had reported previous 
histories of opioid detox and accidental overdose; however, only 50% were reported as being 
referred to opioid treatment programs (OTP) [37]. 
In the Commonwealth of Massachusetts, according to a 2011 – 2015 opioid death analysis, 
the opioid-related overdose death rate was found to be 120 times higher for returning citizens from 
prisons and jails, compared to non-incarcerated Massachusetts residents [38]. Mortality rates were 
also significantly higher within the first month at 200 deaths per 100 person-years [38]. Out of the 
near 54,000 returning citizens identified during this period, three in five were considered homeless 
and more than 50% were diagnosed with a serious mental illness (SMI)—of which, more than half 
were also living with an OUD [38]. An additional 25% of inmates ever received treatment during 
their incarcerated period [38]. On average, overdose decedents were in their mid-30s, White non-
Hispanic men, less likely to have an education beyond high school, more likely to be single, and 
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working in the blue-collar industry. The analysis also identified a 12-fold increase in opioid-related 
deaths among returning citizens from 2011 to 2015—with nearly 50% of all overdose deaths in 
2015 being attributed to the formerly incarcerated.  
Central Appalachia presents its own burden of SUD, especially in distressed West Virginia 
counties where geographical isolation, economic underdevelopment, and health disparities [39] 
are most pervasive compared to the rest of country [40]. Not surprisingly, in 2017, West Virginia 
continued to lead the nation with the highest overdose death rates at a rate of 57.8 per 100,000 
[41]. In West Virginia’s most recent 2016 overdose fatality analysis, 56% of 830 overdose 
fatalities reflected histories of incarceration, with fentanyl contributing to the largest percentage 
of cases among the 35-44 age group [42]. For men incarcerated within 12 months prior to death, 
28% died within first month of release; this number was 21% for females [42]. Once again, 
decedent demographic characteristics included individuals in the blue collar workforce, unmarried, 
and reflecting a poor educational background with 46% of returning citizens in this category dying 
within month of release [42]. 
In the largest study ever conducted in the U.S. across an extended follow-up period of time, 
2000 – 2015, North Carolina decedent cases yielded significantly elevated mortality risk rates of 
74 and 40 times greater for heroin and opioid overdose in the first two weeks post-release, 
compared to the general public [43]. Opioid overdose fatalities were highest for non-Hispanic 
White men between ages of 26 – 50, and especially prevalent among former recipients of substance 
abuse and mental health treatment during more than one past reincarceration term [43]. Out of the 
nearly 230,000 returning citizens surveyed, researchers found that approximately 70% had a 
substance use disorder [43]. Even though two-thirds received some form of substance use 
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treatment that did include MAT, the forced withdrawal policy at the prison was said to have 
propelled the overdose rates following release [43].  
This data confirms that returning citizens with opioid use disorder are subject to an elevated 
risk of overdose and post-release death [44]. Mortality linkage studies matching correctional health 
systems with vital statistics can inform quality improvement efforts in correctional health care 
delivery, especially regarding disparities in substance use care [37]. These findings further suggest 
the need to engage law enforcement officials and criminal justice decision makers in reforming 
their health care delivery system and establishing policy that provides evidence-based practices 
that are effective in American communities [37]. By the same token, if returning citizens are to 
achieve upward mobility over time, continuity and coordination of substance use treatments must 
span across the typical termination period at release.  
2.2 MAT in U.S. Criminal Justice Systems 
Despite the increased level of vulnerability and adverse consequences impacting the 
returning citizen and their respective community, MAT continues to be underutilized in 
correctional institutions, such as drug courts [45], divisionary programs [20], jails [46], and prisons 
[18]. Even though the U.S. became the first country to initiate a methadone treatment trial within 
a jail setting in the late 1960s, efforts to build on existing MAT research have been slow to 
permeate the U.S. criminal justice system [47]. In fact, it was not until 1987 that a U.S. jail,  Rikers 
Island Correctional Facility—one of the country’s longest standing model programs for methadone 
treatment, the Key Extended Entry Program (KEEP)—began engaging individuals living with a 
heroin addiction in treatment during incarceration [28]. This was largely initiated in response to 
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the HIV epidemic at the time. KEEP essentially served as a transitional program for heroin-
dependent offenders who were maintained on methadone and then referred to community-based 
treatment centers on release [28]. An 11-year analysis has since identified KEEP’s treatment 
protocols as proactive in facilitating post-release entry into community treatment and reducing 
recidivism [48]. More than two decades later, in 2011, a county jail in Washington, Maryland 
adopted MAT for all medically-eligible incarcerated populations, including pregnant women; 
although still rare, other penal institutions have slowly started revisiting the notion of piloting 
MAT programs of their own [49]. However, few criminal justice institutions will ever screen for 
OUD using a validated measurement tool and even fewer have structured policy that permits MAT 
as a treatment option [50].  
According to a collaborative 2018 report by the National Sheriffs’ Association (NSA) and 
National Commission on Correctional Health Care (NCCHC), drug treatment programs in 20 state 
Department of Corrections only provided methadone maintenance to incarcerated pregnant women 
[49]. On a local and county jail level across the country, fewer than 200 facilities in 30 states had 
any provision of MAT—with the majority of programs limiting their treatment protocol to an 
extended-release injectable naltrexone on the day of the returning citizen’s release [49]. For jails 
that did provide MAT to pregnant women, treatment maintenance was typically withdrawn 
postpartum, [49] which is not a recommended care modality [51].  
Specialty courts and diversion programs also represent a missed opportunity for engaging 
non-violent drug offenders in evidence-based substance use treatment. As of 2018, there were 
3,100 drug court-supervised treatment programs in the U.S [52], with a reported one-third of adults 
on probation eliciting SUD symptomology [53]. Following this trend, Matusow et al. [45] found 
that nonmedical use of prescription opioids was more pervasive (66%) than reported heroin use 
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(26%) among drug court participants. In principal, drug court programs aim to lessen recidivism 
by diverting drug-dependent offenders through supervised community supportive services, which 
is predominantly inclusive of appropriate SUD treatment. However, despite the National 
Association of Drug Court Professionals (NADCP) approval of MAT [54], discrepancies in drug 
court treatment philosophies continue to persist with the majority not recommending or allowing 
MAT for OUD. A national survey in 2013 reported that, among 103 drug courts in 47 states, only 
47% permitted some form of agonist therapy [45]. Among drug court correspondents, 98% 
reported that a portion of their drug court participants were opiate-dependent [45]. Other recent 
studies have found that drug court clients were among the least likely of justice-involved 
individuals to receive or be referred to opioid agonist therapy [20]. Additionally, data collected 
between 2010 and 2015, from abstinent-based drug courts found that opiate-dependent drug court 
participants were over 80% less likely to graduate from the program, compared to non-opiate 
offenders [55]. Therefore, efforts within this extension of criminal justice treatment need to 
reevaluate policy structure that expands access to the most up-to-date standard of care for opiate-
dependent offenders [20]. 
2.2.1  Evidence-Based Treatment 
A significant body of research on MAT has demonstrated strong clinical outcomes in 
achieving abstinence and long-term recovery, in both, general and criminal justice populations. 
All evidence-based treatment formulations of MAT have been approved by the Food and Drug 
Administration (FDA) to treat opioid use disorders [56]. The Centers for Disease Control and 
Prevention (CDC), the National Institute on Drug Abuse, and the World Health Organization have 
also acknowledged its medical value in treating opioid addiction [56]. Other national organizations 
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such as the National Association of State Alcohol and Drug Abuse Directors (NASADAD) and 
the National Institute on Drug Abuse (NIDA) have released formal statements supporting the 
dissemination of medication treatments for opioid dependence within the CJS [57]:  
“Medications are an important part of treatment for many drug abusing offenders. 
Medicines such as methadone, buprenorphine, and extended-release naltrexone 
have been shown to reduce heroin use and should be made available to 
individuals who could benefit from them.” [58] 
Because SUDs are heterogeneous in nature, involving a complex range of psychological, 
social, biological, and genetic factors, there has been substantiated acceptance of OUD as a chronic 
medical condition [59]. For example, SUDs often undertake several underlying characteristics, 
notably: all symptoms and impairments owe a certain degree of dysfunction to brain chemical 
imbalances; they frequently co-occur with other debilitating mental health conditions; the etiology 
and symptom expression is strongly influenced by the interplay of social determinants; they are 
often associated with stigma and discrimination; and they frequently take a relapsing cycle [11].  
Although SUDs have traditionally been treated through separate behavioral health delivery 
channels, with an emphasis on abstinence-based models of care that include a variety of 
psychosocial approaches [60], the American Society of Addiction Medicine (ASAM) defines 
addiction, in part, as a “primary, chronic disease of brain reward, motivation, memory and related 
circuitry”[59]. By the same token, addiction does not absolve the offender of responsibility from 
misuse of illicit drugs or other criminalized behavior, but does underscore the importance of 
understanding how neurologic deficits may exacerbate physiological conditions outside the control 
of the drug-involved offender [61,62]. From a biological framework, medical practitioners and 
well-versed substance use experts can aid corrections officials in making informed decisions that 
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recognize OUD as a chronic disease, comparable to diabetes, asthma, hypertension, or cancer—
all necessitating medications [61,62].  In light of the contributing variables of addiction, the 
chronic disease model, as applied to OUD, necessitates efficacious biological treatments, even for 
opiate-dependent offenders who have undergone stringent detoxification during incarceration 
[59,61,62]. 
Given the pharmacological advantage of administering MATs to opiate-dependent 
offenders, the scientific evidence-base for MAT and its physiological effects of opioids are well 
studied. On initial use, opiates permeate the blood-brain barrier, which serves to protect from 
fluctuating neurotransmitters capable of disturbing neural function, and attach to receptors on the 
brain cell, activating a rush of neurotransmitters generating a euphoric sensation [63]. After 
continued use or misuse, physiological dependence can contribute to heavier opiate use over time 
[63]. The medications used to treat opioid dependency act on these same opioid receptors, 
particularly the mu receptors. Each drug treatment has its own distinctive pharmacological 
properties and safety profile, implying that the same mode of treatment may not work for everyone, 
as each individual comes with their own history and level of addiction. These medications work 
in one of three ways in tempering these physiological risks: full opioid agonists, partial opioid 
agonists, or full opioid antagonists.   
Methadone is a full opioid agonist. Other substances acting as full agonists include heroin, 
morphine, oxycodone, and hydrocodone. Individuals with opioid use disorder can be given 
methadone to activate the same opioid receptors but are absorbed into the blood over a longer 
period, neutralizing withdrawal symptoms and severing the psychological link between drug 
initiation and euphoria [64]. Methadone is orally administered. It distributes widely throughout the 
body and is broken down slowly. Because of this, methadone is slower to start working and 
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remains active in the body for a long time. Although methadone is a full agonist, it does not 
produce the same euphoric effects as heroin, oxycodone, or other full agonists, enabling people 
taking it to lead productive and fulfilling lives. It is imperative to understand that methadone is a 
maintenance medication, that treatment length can vary, and it is not a cure. Maintenance 
medication qualities are geared towards re-stabilization and control of an illness or its symptoms 
over time, and remain effective only for the course of the treatment’s length. Furthermore, when 
doses are appropriate, methadone improves treatment retention and, as a result, decreases relapse 
and the health and criminal problems associated with illicit opioid use [47]. Long-term methadone 
maintenance therapy is more effective than either detoxification with methadone or abstinent-
based treatment in decreasing heroin use and retaining patients in treatment [65,66].  
Buprenorphine is a partial opioid agonist. It can be used as a product by itself containing 
only buprenorphine hydrochloride (e.g. Subutex), or as a combination product with naloxone (e.g. 
Suboxone, Zubsolv). Because naloxone is an antagonist, administering a buprenorphine 
combination activates the receptors in the brain, but to a less impactful degree than a full agonist 
[64]. As a partial antagonist, the naloxone blocks additional harmful opioids from triggering 
receptors while carrying out its small opioid reuptake to suppress withdrawal symptoms and 
cravings [63]. Thus, the drug formulation is known to divert individuals from misusing or abusing 
the medication, especially given its ceiling effect. A review of trials has found that buprenorphine, 
taken at high doses (16mg), can effectively reduce illicit opioid use and retain patients in treatment 
compared to placebo [67]. When comparing the treatment efficacy between buprenorphine and 
methadone, studies have shown that buprenorphine appears to be as effective, dependent on dosage 
sequences [67]. Furthermore, among justice-involved individuals, buprenorphine was found as the 
more desirable treatment regimen to engage in prior to correctional release [68].  
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Naltrexone is an opioid antagonist. Thus, it blocks the full effects of opioids and requires 
patients to be detoxed completely from opioids, typically 7 to 10 days, before initiating treatment 
[64]. Unlike the daily dosage requirements associated with methadone and buprenorphine, an 
extended-release injectable can be administered once a month. Because the injectable form of 
naltrexone has no diversion or abuse potential, it is not a controlled substance. This offers an 
alternative to agonist therapy. Even though the extended-release injectable naltrexone has not been 
studied as in depth as its counterparts, research indicates that it can improve patient adherence to 
the medication and increase treatment retention [47,69]. Treatment retention affords clinicians 
time to link patients to psychotherapy and community programs and services that will support the 
positive social adjustments patients will need to make [47]. Injectable naltrexone has also been 
found to be effective in reducing relapse to opioid use criminal justice populations as well [47]. 
2.2.2  Barriers to MAT Implementation 
Even with the current literature and contribution of more than forty years of community-
based research evidence, primarily focusing on methadone maintenance, the U.S. continues to lag 
behind many developed countries in providing MAT to justice-involved populations [47]. 
Ideological objections and adherence to the medical model of addiction, in part, may be the most 
prevalent factors in upholding a medication-free treatment approach within the CJS [20,45,70]. 
Such gaps in treatment approaches may be due to administrative personnel who lack sufficient 
knowledge of MAT, including stigmatizing beliefs toward MAT and its efficacy in treating 
substance use disorders [71,72]. Some corrections officials also believe MAT to be “exchanging 
one addiction for another” [72]. This mentality is especially widespread among drug court officials 
who have established policy and partnerships with abstinent-based programs in the community 
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[45]. Other obstacles were associated with lack of sufficient medical staff and security concerns 
regarding medication storage [73]. Insufficient linkages between penal institutions and 
community-based MAT providers have also been cited as an organizational-level barrier to 
treatment referrals [71,73]. Other barriers to MAT include costs associated with the medication, 
potential for drug diversion, and negative public and patient opinion about treatments such as 
methadone and buprenorphine [20,45,70,72]. 
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3.0 Literature Review 
Overall, among criminal justice populations, MAT has been shown to reduce drug abuse, 
specifically among injection-drug users, reduce recidivism, protect against overdose, and increase 
long-term community-based treatment retention rates. Furthermore, studies, including systematic 
reviews, have concluded that MAT cuts all-cause mortality among opioid addiction patients by 
half or more [56]. More specific literature pertaining to implementation in correctional facilities, 
have backed opioid agonist therapies in decreasing risk of overdose and preventing mortality 
among this subpopulation. The following literature specifically pertains to research conducted 
within the CJS that asserts MAT as a protective agent against various harmful post-release 
community outcomes, most notably, mortality.  
3.1 Kinlock et al. 
In its infancy, and in response to significant community concerns among Baltimore drug 
treatment providers and corrections officers, a first prison-based methadone pilot project was 
initiated in 1999. Based off Kinlock and colleagues’ [74] preliminary findings among a small 
sample of 20 prisoners, of which 53% were found to be retained in community-based treatment 
six months post-release,  a large-scale study emerged by the principal investigator  incorporating 
197 heroin-dependent participants. Consenting prisoners were randomized into three treatment 
conditions: prison-initiated counseling with community treatment referral on release; prison-
initiated counseling with transfer to community-based methadone treatment on release; or prison-
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initiated counseling and methadone treatment with transfer to similar community-based treatment. 
In-prison counseling and methadone was provided by the same community treatment provider, 
which was then continued upon release by the same returning citizen. A 3-month post-release 
assessment was then conducted. Significant findings included: both groups, prison-initiated 
counseling and methadone, and prison-initiated counseling with methadone community transfer, 
resulted in 70% and 50% entering treatment. This was in stark contrast to 8% in the counseling-
only group entering community-based treatment. Of the treatment conditions, counseling-only 
participants were also found most likely to use heroin and be reincarcerated. Most notably, 90% 
of individuals who initiated methadone pre-release were found to be retained in community-based 
treatment, 10 days post-release. Results indicated that in-prison methadone maintenance prolonged 
treatment retention and acted as a protective agent against relapsing and reincarceration, especially 
within the first 10 days, which are the most critical in regard to preventing overdose mortality [74]. 
3.2 Brinkley-Rubinstein et al. 
Other studies have found that the rate of MAT retention in community-based treatment 
centers following release increases when MAT is initiated in correctional facility pre-release [75]. 
A randomized control trial assessed 12-month outcomes with 179 participants (people incarcerated 
for six months or less), including 128 who were treated and 51 who did not receive methadone 
treatment. Results found that individuals on methadone were less likely to use heroin and engage 
in injection drug use, as well as reported fewer non-fatal overdoses due to continual engagement 
in community-based treatment, per 12-month follow-up interviews. Forced withdrawal from 
methadone reduced likelihood of MAT engagement long-term. Findings indicate that providing 
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methadone to incarcerated populations pre-release impacts long-term treatment retention in the 
community and reduces the risk of fatal overdoses post-release [75].  
3.1 Green et al. 
In a recent research study conducted in July 2016, the Rhode Island Department of 
Correction (RIDOC) began implementing a new model of protocoled treatment, making accessible 
three forms of MATs (methadone, buprenorphine, and naltrexone) to all inmates screened with 
OUD. Outside community vendors/providers assisted with having all sites operational by January 
2017. To determine the efficacy of this new MAT expansion, this research study utilized a 
retrospective cohort analysis by linking data from the Rhode Island Office of State Medical 
Examiners for all identified fatal overdose cases occurring from January 1 to June 30, 2016, and 
from January 1 to June 30, 2017, to data from RIDOC inmate releases. Tests compared differences 
in decedent (individuals recently incarcerated if they died within 12 months of release from 
RIDOC) characteristic groups between 2016 and 2017. Within the 2016 group, results determined 
that 26 of 179 individuals (14.5%) died of a fatal overdose following recent incarceration, 
compared to 9 of 157 individuals (5.7%) in the 2017 period. This represents a 60.5% reduction in 
mortality. Based on these results, we are able to better identify the value of expanding MAT 
options in correctional facilities to reduce mortality risks of inmates (post-release), since prior to 
this study, only methadone had been offered [50]. 
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3.2 Magura et al. 
The following study implemented one of the first jail-based buprenorphine pilot programs 
in the U.S. [76]. Within Rikers Island Jail in New York City, 116 heroin-dependent offenders (not 
currently enrolled in community-based methadone treatment and sentenced 10 – 90 days) were 
randomly assigned to either a buprenorphine or methadone treatment group. Both treatment groups 
yielded high completion rate during jail period, however, the buprenorphine group (48%) was 
found to report to their post-release community center significantly more often than the methadone 
group (14%). Inmates in the buprenorphine group also reported a significantly higher (93%) 
intention to remain in community treatment following release than the methadone group (44%). 
No difference was found between treatment groups in regard to self-reported post-release 
reincarceration. Thus, a preferential treatment for buprenorphine maintenance in the community 
appears to be evident. Additionally, the study also noted differences in the cost and staff time of 
administering both medications. Because buprenorphine tablets were used in the study, 
approximately 15 min per inmate per day were used in preparing for, dispensing, and monitoring 
the ingestion of the medication. This was compared to 1 – 3 minutes in delivering liquid methadone 
[76].   
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3.3 Lee et al. 
In one of the first studies conducted within the CJS using Vivitrol, a multisite, randomized, 
controlled trial showed that extended-release naltrexone (Vivitrol) could be a promising practice 
in reducing rates of opioid relapse [77]. A total of 153 participants were assigned to Vivitrol and 
155 to treatment as usual (TAU) (e.g. brief counseling, and community treatment programs 
referrals). Over the course of the 24-week treatment period, the percentage of participants that 
reported a relapse event was lower among the Vivitrol treatment group (43%) compared to the 
TAU group (64%). However, after treatment period ended, at 6-month period, opioid relapse 
events indicated no difference between the Vivitrol and TAU group. Although there were no 
overdose events in the Vivitrol groups compared to seven in the TAU group, rates of self-reported 
reincarceration rates were nonsignificant in both groups [77]. Thus, it remains uncertain as to 
whether Vivitrol can be protective against reincarceration or long-term mortality. For this reason, 
buprenorphine and methadone remain preferred treatments for many patients. 
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3.4 Gisev et al. 
The scope of this international study was large in nature, integrating four datasets over the 
course of 22-years to analyze the cost-effectiveness of MAT, community-based retention rate, and 
associated mortality rates among prison settings in Australia [78]. The population consisted of 
opioid-dependent offenders between 1993 and 2011 who had previously been in full-time custody. 
A cohort of 47,196 participants were used to determine cost-effectiveness following release (e.g. 
reincarceration). A minority of opioid-dependent participants were found to be reincarcerated 
overtime that saw costs of $3billion between 2000 and 2012 among this cohort. This finding 
offered realistic costs among opioid-dependent offenders in the criminal justice system. Another 
aspect of the study found that among 15,600 first time MAT entrants, 56% on buprenorphine spent 
less than three months in treatment, compared to 30% on methadone. Similar treatment retention 
trends continued after 12 months. This aspect of the study offers substantial evidence for providing 
a more effective treatment option for opiate-dependent offenders, especially over an extended 
period of time. A third aspect of the study found that among 16,715 participants, the hazard of all-
cause death was 74% lower while on MAT in prison setting, compared to not receiving MAT while 
in prison. Finally, an analysis of 16,453 records found that the lowest mortality rate (post-release) 
was seen among those who continued community-based MAT following release [78]. The value 
of this study is three-fold in presenting concrete evidence on the effectiveness of MAT provision 
in correctional facilities. 
Other international studies conducted in criminal justice institutions have also found 
significant favor with the provision of MAT in reducing mortality and reincarceration rates among 
its returning citizens [79–81].  
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4.0 Allegheny County: Opioid Overdose Data Analysis 
In 2017, 47,600 opiate-related overdose deaths occurred in the United States, 
encompassing nearly 68% of all national drug overdose deaths [82]. Pennsylvania—one of the 
three worst states for percent increases in overdose deaths—accounted for 5,456 drug-related 
overdose deaths in 2017. This reflects a rate of 44.3 deaths per 100,000 persons compared to the 
national rate of 22 per 100,000 [83]. Fentanyl was detected in 67% of these fatal overdose cases—
a more than 1,400 case incident increase from 2016 [83].  
Allegheny County, currently ranked second in drug overdose deaths among all counties in 
Pennsylvania, has experienced fatal overdose rates higher than those seen in many other states in 
the country. It has thus become imperative to track this epidemic, specifically in Allegheny County 
where 735 drug overdose deaths were documented in 2017, up from 650 in 2016, 424 in 2015, and 
342 in 2014 [84].  
Using data from the Allegheny County Data Warehouse, which tracks and identifies human 
services utilization [85], an Opioid-Related Overdose Deaths Report (2008-2014) was released. 
The report identified the number of individuals who had been incarcerated in Allegheny County 
Jail (ACJ), as well as length of time from jail release until fatal overdose. Out of the 1,399 who 
died from an opiate-related overdose, 531 cases or 38% had previously been incarcerated in ACJ 
in the past [86]. An additional analysis found that 211 of 531 people (39.7%) had been incarcerated 
and released from jail within the year proceeding death. However, the greatest proportion of these 
deaths (54 of 211, or 26%) occurred within the first 30-day period following jail release; more than 
half (109 or 211, or 52%) occurred during the first 90 days [86]. 
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This trend continued in the most recent Opioid-Related Overdose Deaths report update 
(2015-2016), where 448 of 910 or 49% decedents had ever passed through ACJ [84]. This is in 
stark contrast to the 38% in the prior reporting period (2008-2014). Moreover, the 2015-2016 
report found that, 164 of 910, or 18%, of people had an incarceration and release from jail in the 
year prior to death, compared to 15% in the previous report (2008-2014). Again, the largest number 
of overdose deaths, 43 of 164, or 26%, occurred during the first 30-day period following jail 
release, and approximately half (77 of 164, or 47%) occurred during the first 90 days [84].  
 
 
Figure 1. Time Between Overdose Death and Jail Release or Most Recent MH and SUD Encounter Among 
Those with Past Year Encounters: 2015-2016  
4.1 Allegheny County Jail: Substance Abuse Services 
Amidst reported overdose mortality rates, a key question is whether jail treatment programs 
can be effective given the short duration of most jail terms. On one hand, about 95% of individuals 
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in jails and prisons will eventually be released to reintegrate into communities, and with effective 
drug treatment, jails can serve as point of interceptions to alleviate recidivism and relapse rates 
[87]. On the other hand, sustained treatment may run a higher risk of being hindered, with one-
third of U.S. jail inmates being released and another one-third being admitted within the same 
week [87]. With only 61% of U.S. jails providing some form of drug intervention—the majority 
offering only drug education—there is certainly opportunities for service improvement [87]. 
However, because one of the major impediments to successful reentry is drug abuse, there remains 
a need to research and assess substance use protocols and treatment methods within the CJS [87].  
With the prominent availability of heroin and fentanyl affecting 97% of Pennsylvania 
counties and the presence of fentanyl-related substances ever increasing at a rate of 400% from 
2015 to 2017 in fatal overdose cases [83], Allegheny County Jail’s pre-release population is not 
immune to the opioid epidemic. Therefore, Allegheny County Jail’s current substance abuse 
services will be examined. Per the description of services found on Allegheny County’s Drug and 
Alcohol website, the current drug and alcohol (D&A) rehabilitation program consists of the 
following steps:  
Upon arrival, inmates are screened for substance abuse dependency during intake at the 
jail. Intake nurses notify clinicians of positive screens, who then conduct D&A assessments. 
Assessments are also conducted upon inmate request or referral from staff. Once assessed, inmates 
may be transferred to a Treatment (5MC) or Education (5E) program housing unit/pod, or may be 
referred into other services [88]. 
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4.1.1  Licensed Drug and Alcohol Program Pod (5MC) 
5MC (pod/unit) is a licensed D&A, non-hospital, rehabilitation program. The program is a 
level 3C (Long Term Residential) program under the Pennsylvania Client Placement Criteria 
Assessment (PCPC). The client stays in the program for 12 weeks during which they receive 
intense D&A therapy, groups and one-on-one counseling services, and focus on topics such as 
relapse prevention, increasing motivation, emotional self-regulation and natural highs, to cite a 
few. Upon completion, the client may return to 5E (pod/unit) to participate in aftercare or they 
may return directly to the general jail population [88]. 
4.1.2  Drug and Alcohol Education Pod (5E) 
The D&A education pod provides a structured living environment with D&A services, 
including triage, education, and aftercare. Clients are assessed to determine appropriate level of 
care. Clients recommended to 5MC inpatient services or Family Based D&A education (Re-Entry 
Center) will remain on 5E and participate in drug and alcohol classes while waiting for a space to 
be available in either of these programs. Clients referred to in-house Drug and Alcohol 
Education will complete a 12-week program. Upon completion they will be discharged from 5E 
[88]. 
A 16-week Drug and Alcohol Aftercare curriculum is provided on 5E for clients who have 
completed either inpatient D&A (on 5MC) or the Family Based D&A program (Reentry Center). 
Those who complete the 16-week aftercare may remain on 5E as a graduate participant or return 
to the general jail population [88]. 
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4.1.3  Drug and Alcohol Education Classes 
Family-based D&A program focuses on topics such as lapse and relapse prevention, 
increasing motivation and the effects of addiction on the family. Eligible inmates are assessed by 
the provider for eligibility to participate in family-based services. The program consists of 12 
weeks of group education, 4 days per week (Monday - Thursday), for 3 hours per day. The 
Addiction and Trauma program offers gender specific D&A education for women. The program 
is a 12-week education curriculum and meets for three hours each week [88]. 
4.1.4  Jail Alternative 
Those who qualify undergo treatment and a recovery program (in the community) and are 
not incarcerated. The jail works with the Department of Human Services (DHS) and the courts in 
implementing this program [88]. 
4.1.5  Outpatient Drug and Alcohol Treatment 
The Outpatient D&A program offers individual and group D&A therapy to clients on a 
weekly basis. The program is based on a continuity-of-care model with outpatient services 
beginning in the jail and continuing after release. After release, the program facilitates a transition 
to community-based outpatient D&A services with a variety of providers [88]. 
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5.0 Methods 
5.1 Participants 
A total of 15 community stakeholders within Allegheny County completed semistructured 
qualitative interviews and a survey for this study. The study sample included people 18 years or 
older working in Allegheny County, Pennsylvania. The majority of participants were male (67%, 
n = 10). The group had a high level of educational attainment, with approximately a third reporting 
that they had completed a graduate degree. Initial participants were recruited from an Opioid 
Advocacy Forum provided by Pennsylvania Harm Reduction Coalition. Thereafter, a combination 
of purposive and snowball sampling was used to recruit participants with a focus on obtaining a 
broad range of stakeholders with differing professional backgrounds associated with providing 
services to returning citizens in Allegheny County. Participants within this sample included: 
criminal justice workers, community service providers, health care providers, public officials, 
emergency medical service personnel, and law enforcement officials. 
In order to decrease barriers to interview participation and assure participants of the 
confidentiality of their responses, interviews were either conducted in a private location at the 
participants’ place of work, via private phone calls, or in other places designated by the 
interviewee. Participants were assured that their responses would not be shared with their 
organization, that their names and other identifying information would be removed from the 
transcripts, and the recordings would be destroyed at the conclusion of the study. This study was 
approved by the Institutional Review Board of the University of Pittsburgh. 
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5.2 Semistructured Interviews and Survey 
Semistructured interviews were conducted by the researcher to the convenience sample of 
15 stakeholders. Interviews involved questions in accordance with the stakeholder’s function, 
service, and connection with previously incarcerated populations. In the process, perceptions, 
experiences, and knowledge of a MAT jail-based initiative in relation to institutional and 
community barriers were examined.  
Additionally, the second part of the interview involved the completion of a survey that was 
administered by the interviewer: Practices, Perceptions, and Barriers that Influence Allegheny 
County Jail’s MAT Use. The survey was developed from a combination of anticipated perceived 
barriers and prior correctional surveys implemented among multiple criminal justice institutions 
[73]. Respondents were asked to rate a series of 17 factors, categorized as barrier statements, that 
might influence Allegheny County’s use of Medication-Assisted Treatment in jail (e.g. negative 
perception of MAT, liability concerns, logistical obstacles) using a Likert-type scale. A rating of 
a 1 indicated the factor was “unimportant,” a rating of 3 indicated the factor was “moderately 
important,” and a rating of a 5 indicated the factor was “very important.” Respondents were then 
prompted by follow-up questions on all factors which received a rating of 4 and 5. If respondents 
were not well-versed in the factor, they were informed they could give a null response. 
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5.3 Data Analysis 
Using data from the interviews and survey, a qualitative matrix analysis was conducted by 
the researcher to streamline categorical constructs from responses across different groups of 
stakeholders. A matrix is defined as “a set of numbers or terms arranged in rows and columns; that 
within which, or within and from which, something originates, takes form, or develops” [89]. In 
this qualitative data analysis, the crossing of several constructs among participants evolved from 
descriptive quotes associated with community concerns and consequences.  In using the matrix 
display, intersections were graphed between constructs and specific groups of participants.  
To further contextualize these constructs, as they would relate to the recovery of an opiate-
dependent offender, the Ecological Systems Theory was implemented to elucidate potentially 
different levels of barriers influencing Allegheny County Jail’s MAT initiative. The theory posits 
that an individual exists within a nest of systems that facilitates or challenges the individuals’ 
behaviors [90]. In this framework example, we take an in-depth look at how these factors may 
exacerbate or facilitate an opiate-dependent offenders recovery condition. 
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6.0 Results and Constructs 
A series of seven systemic constructs emerged from the matrix analysis: provider training 
and attitudes, system policies and issues, continuum of care, probation and drug court, logistical 
issues, partnership limitations, and facilitators. Provider training and attitudes included intrinsic 
attitudes, perceptions, beliefs, and education, or the lack thereof, associated with the introduction 
of MAT as a viable practice within Allegheny County Jail. System policies and issues included 
the current county jail treatment orientation of individuals with OUD and its associated 
consequences on the greater Pittsburgh community. Continuum of care included institutional and 
perceived barriers as related to appropriate medical protocol with individuals in active recovery. 
Probation and drug court included treatment orientations of alternative correctional entities and 
their impact on MAT practice. Logistical issues included perceived constraints associated with 
costs, security, diversion, lack of medical personnel and human resources, and feasibility of 
launching a jail-based MAT program. Partnership limitations included factors and concerns related 
to developing and sustaining MAT provider relationships within jail and community. Facilitators 
included windows of opportunity provided by existing services for initiating a jail-based MAT 
program, as well as positive community initiatives.  
Respondents’ individual stories, perceptions, professional experiences, and knowledge of 
MAT and harm reduction practices highlighted the role each construct played in facilitating or 
barring a jail-based MAT program in Allegheny County. The constructs contextualized varying 
levels of treatment gaps, opportunities, and challenges potentially encountered within Allegheny 
County Jail, of which, also had implications in the extension of that treatment model into the 
community. Furthermore, an overarching theme of “stigma in recovery” emerged from the 
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interaction of these constructs, as responses undertook broader oppositional elements associated 
with lack of social equity, treatment, and support for criminal justice populations living with an 
OUD.  
6.1 Survey Results 
Survey results varied by stakeholder. As previously mentioned, some respondents may 
have been limited in their affiliation and knowledge of survey items, thus, the number of responses 
were moderately inconsistent across the board. One respondent opted to forgo the survey and 
provide a comprehensive synthesis of the processes associated with opiate-dependent offenders in 
Allegheny County Jail. Nonetheless, interviewees were given the freedom to elaborate on all rated 
items, but especially those receiving a score of 4 (important) or 5 (very important). The top 6 
factors were (1) negative perception of MAT as a substitute drug; (2) jail, probation, and drug 
courts favor drug-free treatment; (3) inadequate info at jail about MAT; (4) uninformed of clinical 
effectiveness of criminal justice populations; (5) cost and reimbursement issues; and (6) logistical 
obstacles. 
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Figure 2.  Survey: Practices, Perceptions, and Barriers that Influence Allegheny County Jail’s MAT Use
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6.2 Matrix Analysis 
Additionally, even though survey results did vary by respondent, subsequent interview 
questions supported the formulation and interaction among these constructs in the development of 
the matrix. 
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 Table 1. The Matrix Analysis 
 TABLE 1: THE 
MATRIX 
CONSTRUCTS 
Provider 
Training and 
Attitudes 
 System Policies 
and Issues 
Continuum of 
Care 
 Probation & 
Drug Court 
 Logistical Issues Partnership 
Limitations 
Facilitators 
PA
R
TIC
IPA
N
TS 
Criminal 
Justice Workers 
(3) 
 Deficit in education 
and training among 
“a lot of medical and 
corrections staff” who 
have the “substitute 
of one drug for 
another mentality”  
 Inconsistent views of 
MAT as a recovery 
tool 
 Stigma in recovery 
prevalent in the CJS  
 Gaps in SUD 
treatment due to 
unacceptance as a 
physical health 
ailment, SUD viewed 
secondary. 
 Punitive approach 
taken to SUD services 
  
 Limited 
Subutex/methadone 
treatment to pregnant 
women 
 Vivitrol pilot 
program, “medical 
version of forced 
abstinence” 
 Licensed (DDAP) 
SUD services limited 
to women 
 Lapse health 
insurance coverage 
following release 
 Expectant mothers 
tapered off MAT 4-6 
weeks, postpartum 
  
  
 Discontinuity of 
community-based 
MAT on detainment 
 Reluctance to initiate 
MAT done in 
“beneficence of the 
client” 
 Transient booking 
center interrupts 
referral process due 
to unpredictability 
 Inconsistent warm 
handoff procedures, 
“resources & info on 
Centers of Excellence 
provided” to some 
 Discontinuity of 
medication options 
under program 
 Limited 
programming to 
 abstinence-based 
community recovery,  
  “a lot of those places 
don’t accept MAT” 
 Disapproval of MAT 
as a “front-line 
approach” 
 Reluctance towards 
“mixing of abstinent 
& MAT populations 
on treatment pod” 
 Limited treatment 
space for high census 
count (80 men & 20 
women).  
 Cost issues, but fronts 
medication cost for 
pregnant women to 
avoid maltreatment of 
baby 
 Security concerns 
with methadone 
transport protocol 
 Limited treatment 
personnel  
 Historical 
relationships limit 
partnerships to 
abstinence-based 
community providers 
(e.g. drug court 
preferred providers) 
 Limited community 
MAT rehab programs 
(e.g. Sojourners 
House and Family 
Links for expectant 
mothers). 
 Dissemination of 
Narcan on discharge 
 Established contract 
with methadone clinic 
 Education on 
overdose risks 
provided via Narcan 
video run in jail 
 Openness about 
MAT education but 
contingent on specific 
personnel’s bias 
 Established space, 
“HOPE pod” for men.  
 Deployed specialist 
by DHS for those 
interested in MAT 
 Emergency 
Medical 
 Personnel 
(1) 
 Stigma attached to 
education initiatives 
to mobilize efforts & 
raise awareness in 
communities 
 Adjustment to “new 
concept” of harm 
reduction by EMS, 
compared to 2 years 
ago where “no one 
had heard of it” 
 Overreliance on 
Narcan leads to “lost 
opportunities” in 
community despite 
proactive Narcan 
policy 
 Disconnect between 
engaging returning 
citizens in treatment 
& provision of 
Narcan 
 Disruption in active 
recovery treatment “a 
lot of people in the 
county are in that 
situation”  
 Brief detainment on 
“technical violations” 
hinder continuity of 
treatment 
  
  
 Divide in county 
treatment 
philosophies. 
 Disapproval by 
judges & drug court 
officials “who don’t 
believe in MAT & that 
drives a lot of the 
policy in the county”  
  
  
 Diversion of 
controlled substance 
viewed as excuse for 
not initiating MAT in 
jail setting, “chance of 
diversion 
significantly lower 
than what people 
think” 
  
 Deterrence from 
medications by 
halfway homes due to 
regular urine analysis. 
Leads to use of other 
harmful drugs that 
are not detectable. 
 Limited MAT 
halfway home 
partnerships lead to 
“dangerous choices” 
made by returning 
citizens 
 Educational efforts to 
raise community 
awareness on harm 
reduction is ongoing, 
“we need to build a 
general 4hr block of 
training” 
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TABLE 1: 
Continued 
CONSTRUCTS 
Provider Training 
and Attitudes 
 System Policies 
and Issues 
Continuum of 
Care 
 Probation & 
Drug Court 
 Logistical Issues Partnership 
Limitations 
Facilitators 
PA
R
TIC
IPA
N
TS 
 Healthcare 
Providers 
(4) 
 Untrained medical and 
nurse staff with MAT due 
to “nonrequirement” to 
use it 
Inconsistent 
understanding of when to 
initiate MAT 
 Stigmatized “beliefs and 
misconceptions” 
necessitates education 
 “I had to work two years 
strictly with 
buprenorphine to really 
understand it, and 
actually not to be afraid of 
it” 
  
 Non-medical 
personnel drive 
medical policy 
 Liability placed on 
health systems with 
“significant portion of 
inmates passing 
through ER”  
 Unethical policy 
rooted in “bias 
against MAT” 
Reductionistic 
approach with NA & 
AA meetings, “not 
enough to address 
long term recovery” 
Pitfall of Vivitrol is 
precipitated 
withdrawal 
 Forced detox of 
“stable evidence-
based medical 
treatment” 
problematic and 
“unethical.”  
 Disruption in 
prescribed 
medications due to 
detainment viewed as 
“unethical,” need to 
provide “evidence-
based care that will 
keep them engaged in 
care, keep them alive, 
and keep them 
healthier than any 
other modality that 
we know” 
  
 Bias support for 
Vivitrol as “medical 
therapy” by drug 
courts 
 Inability for drug 
court clients to be 
“honest” about 
medications they 
need. Parole officers 
say, “no, vivitrol 
only.” 
 Inconsistent drug 
court rules & 
sanctions across 45 
different counties 
 Limited clinical staff 
due to “burnout and 
tremendous turnover 
rate” 
Cost of MAT is too 
high in community 
settings, so more 
costly/problematic in 
correctional settings 
 Security concerns 
associated with 
medial policy, 
“medical decision-
making being made 
for security reasons” 
  
  
 Limited direct patient 
navigation/referrals 
from jail, as majority 
of “patients come 
from halfway homes 
that refer to us” 
Unsuccessful 
outreach efforts, 
“we've tried to 
connect with ACJ and 
it hasn't worked out. 
Maybe they’re given 
a list of providers, I 
don’t know” 
  
 Established contract 
with AHN to provide 
all medical and 
psychiatric services.  
Training and waivers 
with med staff “easily 
solvable problem” 
Provision of services 
to “around 80% of 
patients on Suboxone, 
and 20% on Vivitrol” 
in community setting 
Law 
Enforcement 
Officials 
(1) 
 Deficit in proper 
education seen as 
“biggest barrier” 
“Corrections officers and 
warden need to fully 
understand the role MAT 
has in recovery” 
 Stigmatism “always 
attached to methadone 
clinics in communities,” 
need for community 
education to reduce 
stigma associated with 
services.  
  
 Recidivism cycle due 
to limited 
wraparound services 
for returning citizens 
 Overdose cases 
attributed to 
“multiple calls from 
same person” in 
community 
  
 Reintegration into 
community could be 
facilitated/improved 
by MAT receipt in jail 
 Extension of jail SUD 
services to 
community critical  
 for those in recovery 
  
  
 Disapproval of MAT 
may hinder proper 
treatment, but 
dependent on judge, 
“some are old 
fashioned” 
  
  
  
  
 Cost is a “high 
barrier,” because of 
“jail budget and 
understanding what’s 
reimbursable can be 
an issue” 
 Limited resources for 
high census count 
 Security concerns 
due to “contraband 
with MAT” and 
potential for misuse 
 Limited treatment 
options should not 
deter returning 
citizens from 
engaging in 
community-based 
MAT, “I’ve not 
known anyone to 
overdose on MAT”  
Outreach efforts in 
community should 
focus on follow-up 
protocol after jail 
release, “we’d like to 
see a partnership 
where those released 
try to voluntarily 
contact local police 
stations for help and 
follow-up. Our 
number one goal is to 
save lives. All lives 
are precious” 
 Trained to carry and 
use Narcan at all 
times 
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TABLE 1: 
Continued 
CONSTRUCTS 
 Provider Training 
and Attitudes 
 System Policies 
and Issues 
 Continuum of 
Care 
Probation & 
Drug Court 
 Logistical Issues Partnership 
Limitations 
Facilitators 
PA
R
TIC
IPA
N
TS 
 Public 
Officials 
(3) 
 
 Objection to MAT seen 
as “ubiquitous” and 
“prevalent” among 
SUD Tx providers  
 Abstinent-based model 
predominant ideology 
of CJS, “they seem to be 
the last people to get it”  
Stigmatizing “moral 
judgments” formed by 
medical personnel, “in 
2017, we had 1110 
overdose calls in the 
city, about a call every 8 
hours. And you start to 
hear of resources being 
pulled for junkies who 
overdosed again” 
 Lack of equity, “not 
worthy of treatment” 
  
 Unlicensed treatment 
for SUDs a problem 
 Vivitrol viewed as 
“comfortable policy 
because it is not a 
controlled substance” 
 Siloed jail system is 
“rigid” and 
“tremendously 
complex to break 
down”  
 Political fallout 
imminent with “tax-
payer funded system” 
“Public health should 
not be political, 
though” 
 Forced detox protocol 
viewed as unethical, 
“between 2016 and 
2017, 500 some people 
who had been 
engaged in 
methadone and 
Suboxone” had 
treatment terminated 
Liability placed on 
health system 
 Transient booking 
agency presents 
barriers to continuity 
of treatment. People 
are there for 
“undetermined 
period of time and 
may move to other 
facilities” 
 Prevalent abstinence-
based ideology with 
specific judges who 
“refuse to have 
anyone in their court 
using MAT…it’s 
disgusting.”  
 Disapproval by 
judges & magistrates 
who harbor “strong 
opinions against MAT 
as continuing 
addiction. Need to 
“educate judges” to 
not interfere with 
medical treatment 
 Cost per inmate, 
waiver, etc. an issue.  
 Security used as 
“excuse” to not 
implement MATs. 
 Difficult to build 
“leadership” around 
overworked staff 
 Cost barriers due to 
prevailing argument 
that it does not make 
“cost sense” to initiate 
MAT due to 
unpredictability of 
release 
 Limited mobility 
efforts with 
Pittsburgh being “1 of 
130 municipalities in 
Allegheny County” 
 Deterrence from 
MAT by halfway 
homes, “some refuse 
to accept someone on 
MAT” 
 Disrupts coordination 
between rehab centers 
& housing options 
 Limited short-term 
providers that could 
navigate someone 
during brief 
detainment for “only 
2 or 3 days” 
 Lack of “city agency 
presence in jail,” 
although “city 
resources are 
deployed to address 
overdose” 
 Improved screening 
process of SUD 
identification 
Trained doctors 
currently prescribing 
medicine in jail, so 
“logistically easier for 
Suboxone”  
 Dissemination of 
Narcan raises 
awareness. “We 
distributed 6,000 kits 
one year…focusing on 
first responders, 
community groups., 
underground orgs. 
campaign to 
normalize & 
destigmatize Narcan.” 
Community 
Service 
Providers 
(3) 
 Competing and mixed 
views MAT among 
CSPs, “People don’t 
fully understand MAT” 
 Pushback towards 
MAT, “concept of 
counseling has really 
changed with MAT” 
 Bias for Vivitrol among 
abstinence-based 
providers 
 Limited “political 
cover” to provide 
MAT in jail 
 Vivitrol “lobbying” & 
“free doses” seen as 
major reason for 
policy window 
Oriented towards 
corrections, “not 
rehabilitation” 
 Punitive policy “not 
looking to treat SUDs 
holistically” 
 Unethical & 
“disturbing” to take a 
detainee off a “life-
saving medication” 
but due to “lack of 
resources in jail” 
 Limited wraparound 
around services for 
released individual  
 Gap with health 
insurance coverage 
after jail release, 
“they’re going to get 
cut off with MATs” 
 Bias towards “12-step 
help groups, NA 
meetings…they don’t 
believe in MATs” 
Misperception of 
drug courts position 
on MAT 
 Limited channels of 
service with JRS and 
Probation dept. being 
two largest entities to 
work with drug court 
 Limited navigation 
due to “closed 
environment” that 
hinders “capacity for 
outside provider” to 
implement services” 
 Security concerns, 
 “so that's the fear, 
that’ll disrupt the 
community, fights, 
riffs, issues on pod” 
 Fiscal priority on 
“reducing resources” 
 “imagine med line 
with MAT, going to 
need to hire more 
staff” 
 Complex interplay of 
factors when 
establishing jail-
community 
partnerships.  
 Lack of established 
requirements for 
provider contract 
terms. Profit element 
seen as obstacle. 
“Providers are 
everywhere, but who 
gets the contract?” 
Hesitance towards 
MAT orientation by 
halfway homes, 
“limited by their own 
providers” 
 Opportunities for 
drug courts to be 
“safety nets” 
 Facilitated linkage by 
some peer navigators 
that will meet with 
prospective MAT 
patients in jail 
 Improvement of SUD 
services contingent on 
allowing providers 
“to get in there and 
established on a 
certain pod” 
 Supportive 
relationship with 
DHS for MATs 
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TABLE 1: 
Continued 
CONSTRUCTS 
 Provider Training 
and Attitudes 
 System Policies 
and Issues 
 Continuum of 
Care 
Probation & Drug 
Court 
 Logistical Issues Partnership 
Limitations 
Facilitators 
 Researcher’s 
Critical 
 Reflections/ 
 Comments 
 Education and buy-in 
among jail-to-
community SUD 
providers required to 
reduce/eliminate 
stigmatized beliefs 
associated with harm 
reduction and MAT 
 Training among jail 
personnel, mental 
health, and substance 
use counselors should 
be holistic and inclusive 
of proven best practices 
for SUD treatment  
  
  
  
  
 Medical policy 
should be driven by 
EBP, appropriate 
public health experts, 
substance use 
counselors, and 
promulgate equity 
among all jail 
populations 
  
 Discontinuity of 
community-based 
MAT on detainment 
hinders opiate-
dependent offender’s 
active recovery 
Transient jail 
population 
complicates treatment 
referral processes 
 Coordination of 
information between 
judges, defense 
attorneys, 
prosecutors, and jail 
should include risk 
assessment & 
consider history of 
SUD services 
  
  
  
  
  
   
 Inconsistent avenues 
of information, 
sanctions, and 
treatment orientation 
within drug court 
hinder EBP, and is 
further complicated 
by other surrounding 
county drug court 
policies 
 Participation in drug 
court program 
contingent on 
judges/magistrates’ 
bias or approval of 
MAT 
Misrepresentation of 
defendant’s preferred 
recovery path 
Lapse in treatment 
plan collaboration 
with defendant leads 
to dishonest 
adherence to 
treatment terms 
 Limitations 
associated with 
clinical personnel 
turnover/burnout, 
financial constraints, 
and security with 
drug diversion are 
warranted, but not 
insurmountable.  
 Concerns with 
treatment space that 
would mix abstinent- 
based and MAT 
populations  
 
  
  
 Expansion or 
development of 
comprehensive list of 
providers (health care 
and behavioral 
health) that would 
holistically treat the 
returning citizen   
 Navigation and 
referral system from 
jail would be 
facilitated by warm 
handoffs between 
those established 
partnerships geared 
towards both, short 
and long-term 
recovery initiatives  
 Limited community-
based MAT 
partnerships and 
halfway homes that 
may hinder a housing 
applicant from 
coming in with MAT 
  
  
 Opportunity to 
expand services due 
to existing contracts 
and partnerships 
within jail between 
AHN and community 
methadone clinic for 
pregnant women  
 Openness among 
City, DHS, primary 
health provider, and 
some jail personnel to 
establishing 
comprehensive 
educational and 
medical MAT 
program within jail 
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6.3 Provider Training and Attitudes 
Participants shared their professional experiences, beliefs, and understanding of harm 
reduction, addiction, and MAT, as it relates to criminal justice populations. Among the majority 
of stakeholders, there was a predominant consensus that MAT and the concept of harm reduction 
is hindered by the lack of education and punitive approach taken by correctional institutions. One 
of the criminal justice respondents (#3) noted, “in my experience, they are not as familiar with it—
I don’t believe any of them have too much education.” A law enforcement official (#5) highlighted 
the importance of breaking down this stigmatic barrier, particularly within the jail:  
I think that there's a bias against methadone and suboxone because it doesn't make 
people feel bad, you know, it doesn't make people suffer. It's moralistic. The biggest 
barrier is proper education on MATs role in recovery, and properly informing 
everyone from clinical staff, to corrections officers, to warden, to county 
controllers, and everybody, needs to understand fully what the roles of MAT are in 
recovery, how they can work, and then work towards a solution to integrate them 
into healthy recovery. 
Deficits in appropriate training and information regarding MAT, as a recovery tool, were 
further attributed to systematic and personal stigmatization of addiction. This included perceptions 
of how jail staff felt about MAT and harm reduction practices, in general. One health care 
respondent (#6) stated, “the problem is there’s still a lot of abstinent-based 12-step people who 
believe you’re just substituting an addiction…I know for a fact that a lot of people in the county 
jail administration have that perception.” Throughout the interview process, participants 
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continually perceived criminal justice agents as having negative views, including stigmatizing 
moral judgements, about MAT. Another criminal justice worker (#2) expounded on this further: 
A lot of medical and corrections staff don’t understand the evidence behind it and 
have the “substitute of one drug for another mentality” or that it will be abused. 
Some staff here see it as an alternative drug, that you’re just getting high, but that’s 
rarely the case. Even management have elements of that [mentality]. They don’t 
see it as something that will help someone achieve their recovery goals. 
Lack of training initiatives may be largely contributed to the “multidisciplinary” nature of 
the jail regarding the division of departments (e.g. mental health, substance abuse, medical, 
security, etc.) and burdens associated with burnout, underpayment, and high turnover rate among 
staff. This would undoubtedly make it “difficult to ensure everyone had the same course of 
training,” noted a public official (#10).  Sustainability of trained and informed staff present a huge 
challenge within an “enclosed environment,” which may hinder communication and agreement 
among stakeholders in “leadership roles.” Because MAT and harm reduction is still perceived as 
a relatively new concept in the addiction recovery world, establishing a mandatory uniform 
training module that consistently addresses the benefits of engaging in such treatment comes with 
its own barriers. For instance, health care respondent (#6) felt strongly about prioritizing the 
initiation of treatment regardless of other commonly perceived requirements: 
We're pushing Suboxone as a treatment modality. We're really having 
conversations with providers about this whole concept of MAT, that somehow you 
have to have complex steps associated with therapy, drug treatment, 12-step 
meetings, and everything in order for people to get Buprenorphine. We're really 
pushing back against that. We feel that the most important thing for a person to 
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have is Buprenorphine because that is the drug that will keep them alive and save 
them. And so, we see that as harm reduction, but if someone isn't willing to engage 
in behavioral treatment, or drug and alcohol treatment, or 12-step programs, but 
they're willing to take suboxone, then that's that. It's sort of akin to patients of mine 
who come in and you know, were screened for depression and they're clearly 
depressed and they need an antidepressant. I'm not going to wait until they see a 
psychiatrist or therapist before I give them an antidepressant. That would be 
unethical. 
Other respondents had completely opposite perspectives of buprenorphine as a facilitator 
for addiction recovery. There was a sense of ambivalence, insecurity, and threat associated with 
MAT among abstinent-based community service providers. A general misunderstanding of harm 
reduction and physiological effects of MAT, specifically with buprenorphine, was noted among 
this group of respondents, as well as a sense of fear that traditional counseling services may be 
replaced. This example depicts how a lack of knowledge about MAT can lead to stigmatic beliefs 
about medications. A community service provider (#12) stated: 
We are losing the whole purpose of the counseling piece and just prescribing these 
medications. Counseling is so limited with MAT. They came up with this idea of 
harm reduction, came in as harm reduction, but now, it’s not harm reduction, it’s 
treatment. We’re saying, here, have eight milligrams of Suboxone three times a day, 
and as long as he’s stable and not thinking about using, it’s a great 
accomplishment. We’re not treating the core of the problem, but the symptoms of 
it. Those are two things people really misunderstand and confuse. I have my own 
private practice, and I see people on Suboxone. But I let them know, listen, that day 
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you come in, I really don't want you to take it because I want you to be present with 
me. Medications usually numb people. 
6.4 System Policies and Issues 
Participants discussed three factors within this construct regarding the structure and context 
of treatment which included, treatment orientation, the Vivitrol pilot program, and Narcan.  
Treatment orientation One of the policies that emerged was limitations on who receives 
MAT during incarceration period at Allegheny County Jail. “Non-pregnant women and men do 
not receive any form of MAT, and for women who are postpartum, they are tapered off of MAT 
in 4 to 6 weeks,” noted a criminal justice respondent (#3). Pregnant women are prescribed either 
buprenorphine or methadone, and if they are not engaged in community-based MAT at the time of 
arrest, “most of the time we’ll initiate it.”  
Furthermore, detainees are screened using a urine analysis. Because MAT is limited to 
expectant mothers, a criminal justice participant (#2) noted, “individuals admitted experiencing 
opiate withdrawal are observed in detox room and given comfort care type medication, like valium. 
We have a detox nurse that assesses for withdrawal symptoms using COWS (Clinical Opiate 
Withdrawal Scale).”  
Following a clinical assessment, inmates are then transferred to the drug and alcohol pod 
(D & A) where they receive substance abuse treatment as noted by criminal justice worker (#3):  
Services provided for inmates with SUDs are residential substance use treatment 
pods. So, for women, we probably see (18 to 20) at a time on a pod with groups and 
individual sessions. For men, probably (70-80) on the pod at a given time with 
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groups and individual sessions. There’s a reentry drug and alcohol education class 
open to general population and substance use treatment pod.  
While criminal justice respondents shared that there were ongoing NA and AA 
meetings offering in jail, discussions and information related to the use of MAT was limited 
to the counselor’s knowledge and preferred practice, as evidence by criminal justice, 
participant #3, “I’ll talk about MAT in groups, but it is not in the structure of the program. 
It depends on the knowledge of the counselor of MAT. Other counselors may not be as 
familiar with it.” Although education on MAT seemed to vary, a public official (#11) was 
weary of denoting any service provided in the D&A pod as treatment: 
So now, you’re put up on the D&A pod and people get treatment. You’ll hear the 
word treatment. I don’t know how you do that when the jail is not a licensed 
treatment facility for substance use. There’s a state regulatory body that licenses 
facilities, like a Gateway Rehab or any of these treatment centers. So, when we hear 
about treatment, it’s kind of hog wash. 
Vivitrol Inmates with pending release dates are afforded the option of receiving Vivitrol 
on their release day, a program that was taken up by reentry. “There’s been a pilot since the fall of 
2017, actually, to do Vivitrol that is paid for by the Pennsylvania Commission on Crime and 
Delinquency – so it’s a special grant program.” This program, in particular, was met with heavy 
criticism from a majority of respondents who denounced the policy effort as being in line with the 
“abstinent-based ideology of the criminal justice system.” Among various respondents, one public 
official (#11) stated:  
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People like it in the CJS because it’s not a controlled substance, it’s a non-narcotic, 
non-opioid, and you do it once a month, people love it and think that’s great. Right 
now, we don’t really have the evidence to say we should or shouldn’t do that stuff.  
Other respondents noted systematic issues associated with how Vivitrol has “embedded 
and latched” itself onto the CJS as marketing themselves as a “blocker,” not a drug. “It’s easier to 
accept a blocker verses a Suboxone,” said health care participant (#7). The majority, especially 
those in the health care field, saw this as a problem with a participant (#6) stating:  
The problem is they've been very heavily lobbied and presented with evidence about 
the efficacy of naltrexone by the company that produces Vivitrol. And they've been 
sold as a bill of goods that this is a really effective treatment. It's not an opiate, you 
know, it really works. It's not divertible, it's not abusable. It'll prevent people from 
dying of an overdose. And in fact, a lot of the evidence really points in the opposite 
direction. The problem is when it wears off people don't want to go get another shot 
because they don't feel well on naltrexone, they continue to feel like they're in this 
chronic state of withdrawing craving. 
Moreover, those in criminal justice noted how difficult it can sometimes be to retain 
returning citizens on Vivitrol. One criminal justice worker (#2) shared a story about how a client 
under community supervision avoided and continually made excuses to prolong receiving his 
monthly Vivitrol shot. “We all know he wanted to use so I told him, you’re either getting the shot 
or you’re going to jail…so that’s how it goes.” Others in the health care profession backed this 
statement, alluding to their professional experiences with having patients on Vivitrol. In particular, 
one participant (#7) stated: 
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Whenever patients on Vivitrol have broken, they get antsy. It's like right on the nose 
after week three.  Some people will experience cravings and symptoms. Some 
people are like, let me try and break that barrier, and they'll start doing heroin 
when they know it's weaker. So, we've seen some of the pitfalls [of Vivitrol], it's 
harder for people to get on it. Some people have gotten precipitated withdrawal 
because you need to be detoxed off. And some people aren't always honest, and they 
start with ReVia, or they just give them the shot, and they weren't honest, and now 
they're in the ICU and withdraw, so it's not like catch-all type thing. 
Among abstinent-based community stakeholders, one respondent (#12) identified Vivitrol 
as the “only treatment modality of all MATs” that could actually work without “interfering” with 
what needs to be on an internal, psychological level. He continued: 
Vivitrol may be the most effective treatment because it’s done once a month and it 
doesn’t have the side effects of methadone or Suboxone, where a person will 
experience withdrawal symptoms or nod off on it. People still get to feel and go 
deep and talk about issues because you know, medication usually just numbs 
people. 
Narcan Another option that is afforded to the pending releasees is the opportunity to be 
discharged with Narcan. In addition, prior to release, criminal justice workers reported that inmates 
do receive education about the risk of overdose, mentioning that there is “Narcan video which 
everyone watches in the jail,” that details “steps” on how to use Narcan and maintain a “buddy 
system” at all times. Emergency medical personnel (#4), particularly, applauded the proactive 
policy efforts of initiating Narcan in ACJ prior to release as overdose rates have “decreased 
steadily as the community has been blanketed with Narcan.” He continued, “we’re probably down 
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about 60% from when we peaked in 2017 because of fentanyl…I’m still treating overdose victims 
1 to 3 times a week, though.” However, he was weary of the extension of that policy discussion 
merely ending with Narcan, stating that people still need to be connected with services that will 
aid community recovery efforts. The respondent went on provide information he had received from 
a homeless outreach coordinator that encapsulated his perspective on the matter: 
He knew of 90 overdoses within past few months, and only 3 of them involved a call 
to 911—what that shows is that there is enough Narcan out in the community and 
people are carrying it and using it which is saving lives, which is fantastic, but then 
on my end, we’re losing opportunities to connect with these people and a system 
and help get them into recovery services. It becomes a lost opportunity. It would be 
very easy for us to say the crisis is over—that’s dangerous to say—and to start to 
roll back on all pressure we are putting on [rehab] programs, when in reality more 
people are using and more people are overdosing, but just not calling 911. They’re 
just using smarter. 
6.5 Continuum of Care 
Out of all constructs, respondents took up the most issue with the termination of all 
detainees’ community-based MAT at jail entry, stating that the “forced detox process” not only 
disrupted “active recovery” and was “unethical,” but placed a “huge liability” on the health system, 
warranting grounds for “lawsuit” cases. “We see a lot of people coming in with an overdose and a 
lot of them have been previously incarcerated at Allegheny County Jail—it's a significant 
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proportion,” noted health care respondent (#6). Thus, health care professionals were the biggest 
proponents of advocating for health equity in the jail, stating: 
Given the fact that one of the leading causes of death for people leaving jail is 
opioid overdose and that a lot of those people, a number of those people come into 
the jail on stable methadone or Suboxone and are taking off of it and denied that 
and then released without it, sort of puts some liability on the health system because 
we're kind of allowing it to happen.  It's kind of like, you know, somebody comes in 
and says we don't believe in insulin. And you know, you're a diabetic and you come 
in on stable insulin and we remove the insulin and detoxify you. And you die. It's 
similar. 
Respondents among the criminal justice, EMS, and health care groups discussed their 
experiences with the discontinuity of medical services with their patients/clients upon 
incarceration, and how a “significant number” in recovery are “hamstrung” by this “misinformed” 
medical policy. Some respondents relayed issues encountered with detainees that came in with 
scripts for Suboxone. For example, another health care provider (#8) noted: 
I know, firsthand, some of my patients had pending court dates where they knew 
they were probably going to go jail and have come back out and told us that they 
smuggled in their own Suboxone strips we prescribed, so I think it would cut down 
on that, especially knowing that medication would be continued during their 
incarceration period, particularly if its short. Patients have told me that they were 
in there for just a few days, and didn’t want to get sick, so they knew that was the 
case, so they made it work.  
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Perhaps, the most telling piece of information painted a picture of how many 
individuals may be potentially impacted by the forced withdrawal policy, as a respondent 
(#11) shared:  
Over a 2-year period, between 2016 and 2017, we found that there were 500 some people 
who had been engaged in methadone maintenance in the 2-weeks prior to their 
incarceration, and about the same, maybe little bit more who had filled a prescription for 
suboxone, paid for by Medicaid or the County. 
However, from opposing perspective, because Allegheny County Jail is a central booking 
agency, there exists the barrier of “unpredictability” within the system, “making it difficult to 
either start or continue a MAT protocol.” Other considerations highlighted that “maybe half or so 
leave within the first 30 days,” and sometimes to other correctional facilities that may not provide 
MAT, “so you have to think about the beneficence of the client.” The criminal justice respondent 
(#3) continued:  
And so, thinking about the ethics of initiating someone on MAT and having to take 
them off because the detox and withdrawal symptoms would be worse. And that’s 
a huge reason as to why we don’t have MAT in the jail, because we don’t know 
where they’re going next – they can be transferred to Westmoreland County who 
may not have it (MAT) or upstate who doesn’t have it.  
Nonetheless, for discharge planning purposes, efforts are made to coordinate for Vivitrol 
or Subutex (for pregnant women) when they are released. Criminal justice workers noted providing 
resources about Centers of Excellence in Allegheny County to inmates interested in engaging in 
community-based MAT, but explained the difficulty of coordinating post-release referrals. 
51 
“Because we don’t have access to the system, a lot of times, our clients are gone and we don’t 
know about it until the next day.” 
6.6 Probation and Drug Court 
In regard to probation and drug court implications, participants discussed a strict abstinent-
based approach taken by judges and magistrates that harbor “strong opinions against MAT,” in 
that, it facilitates the continuation of an addiction. Respondents were also critical of criminal 
justice courts making medical decisions for drug court offenders with medical conditions, such as 
OUD. Some mentioned drug court officials being accepting of Vivitrol as “medical therapy 
because it’s an opioid antagonist.” Public officials and criminal justice workers noted this belief 
as being the “biggest barrier” towards establishing a jail-based MAT program, particularly because 
it eliminated the notion of introducing two other forms of MAT. In the following example, a public 
official (#10) alluded to the importance of turning out for elections given that some judges may 
have a strong foothold on policies that drive the county:  
Judges are some of the most powerful people. I don't think we pay a lot of attention 
to who we elect when we elect judges. Judges make a lot of decisions and they 
really hold the future of a lot of people in their hands and there's nothing that says 
that they need to be using evidence-based practices or be public health experts, 
which is highly problematic. 
More systematic issues were highlighted in regard to managing an estimated 25,000 people 
who are on probation in the county. While the Allegheny County Jail inmate count may be high at 
certain times of the year, for those who are on probation and community supervision, the question 
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of linking probationers to community-based MAT undertakes a more complex scenario. One 
public official (#10) noted the complexity in breaking down the existing silos:   
Even though there’s a lot of momentum, there’s a lot of interest and enthusiasm in 
wanting to do more, to do better, the existing systems are so rigid and hard to break 
down. I mention it because when people are released on probation, they may be 
getting drug tested and as far as I understand MAT, if you’re on opioid replacement 
therapy, it’s going to give you a positive test which could be in violation of your 
terms of release.  
Some participants framed their perceptions of drug court from the views that were 
communicated overtly, through public media outlets. For example, one respondent (#11) 
encouraged the googling of “Honorable Nauhaus Allegheny County drug court…you’ll see his 
position on it. He refuses to have anyone in this court using MAT. Publicly stated. It’s disgusting, 
but it’s public.” Another health care respondent (#7) noted the limitation of strict regulations that 
prevent patients from being “honest” about getting the treatment they want, like Suboxone, “one 
of my patients I just saw was very adamant about it. He said, I’m on federal probation. I don’t 
want my judge to know that I’m even on Suboxone.” Others shared similar experiences about their 
patients feeling like they need “permission” from their parole officers, however, encountered 
resistance, stating, “no, that is not part of the plan. Vivitrol only.” Another respondent (#9) in the 
health care industry shared treatment complications encountered with another nearby county drug 
court: 
I’ve seen that first hand with my patients. I even had a scenario with a patient in 
Butler County who was in drug court and they didn’t allow her to be on Vivitrol, 
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which is not even a controlled substance. I think the abstinence model is pushed in 
multiple realms, especially on the incarcerated population. 
While participants highlighted the need to “educate” and change the negative perceptions 
associated with addiction and MAT in drug courts, other criminal justice workers more closely 
aligned with the innerworkings of Allegheny County drug court had a different take on the matter, 
suggesting, there was a misrepresentation of the Allegheny County drug court team approach. A 
criminal justice respondent (#1) noted that the perception of certain drug court judges may be 
responsible for swaying public opinion:  
As a whole, I would say they are very informed on MATs, you know, there's several 
working parts to that program, but there's a lot of training that happens around 
MATs and the importance of MATs. So there is buy-in, overall, from the team, and 
we do currently have people who do participate in that program on MATs. 
6.7 Logistical Issues 
Cost and feasibility Criminal justice workers raised significant concerns related to the 
financial feasibility of integrating a jail-based MAT program into the county’s tax funded budget.  
Some remarked on the price of medication as being “too expensive” in the general community, 
and alluding to the government as being primarily responsible for failing to resolve “one of the 
biggest health problems in this country at a reasonable price.” And that is just the medication itself, 
“before you say yes, we’ll do MAT, you have to consider the cost of contractors, doctors, pay for 
all their waivers, and consider other organizational logistics.” A county official (#11) summarized 
the logistical cost of such a program:  
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What does it cost, per week, per month, and how long were they incarcerated? What 
would it cost to continue that treatment with about a minimum of 300 people 
needing that, maximum 600? It’s probably closer to 600 people per year to treat 
with both, methadone or Suboxone. There’s a 6fold, maybe 10fold difference in the 
price. And it’s a lot of money, sure. You’ve got landslides, you’ve got development, 
water problems, all this stuff, you’re really going to be put leadership in the jail to 
say we should do MAT on money we don’t have? 
Other participants (#10) responded similarly, stating that it would not make “cost sense” 
to start inmates on MAT because the “average length of stay” would not “commensurate with 
completing the course of treatment.” In the following example, a criminal justice respondent (#3) 
addressed this concern and gave a brief synopsis of a potential scenario that could play out, even 
if Allegheny County Jail became a certified opioid treatment program at some point in the future:  
Say, someone is on methadone and they are being held in ACJ, but have a hearing 
in Butler County. They would need to be transferred to Butler County part of the 
week, but they have no MAT over there, and even though we could technically have 
a partnership with Butler County, that would mean that someone from Butler 
County has to drive over every week that person is there to get their doses and 
that’s just not happening. Butler County is not going to want to take on that cost 
and neither is Allegheny County. 
 In the case where a partnership could be established with a community methadone clinic, 
respondents noted concerns with “transport costs” that the Allegheny County Sherriff’s 
Department would have to undertake on a daily basis. One respondent (#3) was particularly 
concerned with the lack of counseling time afforded to pregnant women in the jail receiving 
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methadone, “from a social justice perspective, 5 minutes of counseling is not effective.” From the 
perspective of contracting a methadone clinic to come into the jail, a criminal justice respondent 
(#2) noted those challenges:  
You’d have to contract with an outside provider, load up all the patients, load up 
all the medications, transport it in a box to a medical professional who’s been 
cleared to do this. This is all federally regulated. Drive over to the jail, go through 
security, up to the D and A pod, open the case and dose every individual 
accordingly. Every single day that has to happen.  
Security and diversion Another barrier that emerged within this construct was the security 
concerns associated with the mixing of abstinent-based and MAT populations within a jail setting. 
Because general and treatment pods within the jail are gender-based, security and drug diversion 
implications may be further complicated if pods are not designated by treatment approach. A 
criminal justice participant (#3) shared their experience:  
Within the substance abuse department, I advocate for MAT pregnant women to be 
in the substance use treatment pods, but I get a lot of resistance from other 
colleagues because the women might entice other inmates to use. It’s not perfect. I 
mean they are a correctional institution and they are trying to manage high-
security protocols, so that (drug diversion) definitely falls within their strongest 
arguments. They have to have an isolated pod. 
This statement was further supported by other community stakeholders who work closely 
with Allegheny County Jail, admitting that “Suboxone is very available on that pod…the women 
who I’ve had in there and who weren’t on MAT, could have had it any day they wanted.” The 
participant (#2) further elaborated on how the “fear” of creating a “black market” could potentially 
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“disrupt the community and cause fights,” and how that would present a major security concern 
for all parties involved. Regardless, outsider perspectives from health care, public, and community 
provider participants continued to push the envelope and condemned correctional officials for 
interfering with an inmate’s recovery solely based on security measures. 
Medical decision-making, at least in this arena, are being made for security 
reasons and not for medical reasons. The warden is making medical decisions 
based on security. And that is the problem and it's really inappropriate. The 
problem is that we have to convince security staff and they're not listening. 
6.8 Partnership Limitations 
Regarding partnership limitations, some community providers and criminal justice workers 
agreed that there is a lack of jail-to-community partnerships. One respondent (#2) indicated that a 
change in the abstinent-based ideology of the jail and drug court would further jeopardize 
community-based partnerships already in place, stating, “there aren’t a lot MAT rehab facilities 
from what I’ve seen, especially those that could navigate someone [who is in jail] for three or four 
days.” Criminal justice workers (#3) also acknowledged the strong relationships held with drug 
court and their preferred abstinent-based community partners, noting:  
MAT would limit folks, especially like JRS, that use abstinent-based treatment 
centers. If we initiate MAT, they can’t go to these centers anymore. So, you have to 
think of the partnerships that may be established with drug court in the county, too. 
That’s a barrier in itself.  
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Similar sentiments were shared between public and community provider participants. One 
(#11) shared a story about his conversation with a leader in a larger rehabilitation facility in the 
region, “she was explaining to me that the halfway staff that she works with adamantly refused to 
accept that someone could be in a halfway house using a medication. Period. Refused to accept 
and work with them.” This example also depicts how stigma in recovery may be rooted in lack of 
knowledge about MAT, ultimately affecting the holistic receptivity of treatment. A medication-
free provider (#12) who had maintained a community relationship with the jail shared his concerns, 
asserting: 
They refer to us through drug court and probation. If the jail decides to move 
towards MAT, they're not going to send anybody. If somebody comes out of jail on 
Suboxone, we have to find a place for that person to go to for Suboxone because 
we're not a hospital. We don't have the ability to have Suboxone here in order for 
us to treat them. 
 Other respondents brought awareness to the lack of partnership initiatives between their 
health provider center and the jail, noting that some of their referrals come from halfway homes 
that are open to Vivitrol. However, “there’s no direct referral process” even though at some point, 
the health center did have a “peer navigator” go into ACJ. After the “long process” the navigator 
had to endure to just be able to establish some kind of presence in the jail, “he recently left and 
nobody has really picked up his role. So, you have to start all over again with clearances and things 
like that.” Since then, the health care participant (#8) claims outreach efforts have been made to 
ACJ, but “it hasn’t worked out.” Another criminal justice worker’s (#2) response correlated with 
this, stating that he has known community service providers who have “really tried hard” to 
establish a partnership with the jail and “they didn’t succeed.” Furthermore, this respondent went 
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on to outline challenging factors facing providers who may have an intention of forming a 
partnership with ACJ:  
I guess it's the politics of it, of having somebody to have that amount of ability to 
navigate their system within their system to implement something of that capacity 
as an outside provider. The jail's a closed environment, so to have that level of 
trust, even for us, there's nobody else who could do what we do, to be able to go in 
there and navigate things. You have to have a relationship with the warden and 
treatment staff, have the history, experience with working in that system. All that 
kind of stuff – it’s just a really, really difficult process. And if you don't have that 
history and experience with working in that system, to bring somebody new is next 
to impossible. 
Finally, EMS personnel indicated the dangers associated with released inmates who are 
then linked to stable housing, particularly in halfway homes where the majority of returning opiate-
dependent offenders are placed. Because of the strict drug-free policy undertaken by the majority 
of transitional halfway houses, “regular urine analysis” are ongoing. Residents within this sober 
living community must then abide by the terms and conditions of the addiction recovery program. 
Thus, the “biggest predicament” cited was the need for returning citizens to seek alternative drugs 
that would not jeopardize their community housing. One positive test could result in a violation 
and immediate expulsion from the halfway home. The EMS participant (#4) went on to detail his 
encounters with such individuals:  
A lot of the released inmates in these halfway homes turn to synthetic cannabinoids 
that they buy on the black market, like K2 or black spice. And so, those don’t show 
up on your analysis, but because they’re lab created and unregulated, there’s a 
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whole range of effects from like opioid toxidrome, to methamphetamine toxidrome 
with seizures, and so they’re going unresponsive, and we don’t have the benefit of 
having Narcan to help them with that. They cause injury to themselves, as well as 
our providers. If there was better access to MAT in the community, you’d see less 
of these dangerous choices people are making. 
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7.0 Discussion 
The current study is the first, to our knowledge, to examine the perceptions, knowledge, 
and policies associated with MAT use among stakeholders who are, either directly or indirectly, 
involved with providing some level of service to previously incarcerated populations in Allegheny 
County. The survey and local context of the interviews illustrate systemic factors that affect the 
treatment processes associated with opiate-dependent offenders within the jail and in the 
community. The seven constructs previously discussed included: provider training and attitudes, 
system policies and issues, continuum of care, probation and drug court, logistical issues, 
partnership limitations, and facilitators.  
In our study, the identified constructs can be framed as ecological factors within some of 
the nested systems. These systems include macrosystem (e.g., societal perceptions and attitudes, 
abstinent orientation, and educational training), exosystem (e.g., system policy, including its effect 
on the continuum of care, and logistical constraints), and mesosystem (e.g., community 
partnerships and probation and drug court programs). These broader ecological influences further 
underpin and expand upon NIDA’s research-based guide on effective principals of drug addiction 
treatment, specifically, how societal perceptions, policy, and community agencies impact 
treatment delivery.  
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7.1 Macrosystem 
For nearly all participants, social and internalized stigma associated with MAT was 
perceived as the most significant barrier in Allegheny County. Many cited to an impending 
political fallout if ACJ were to ever undertake a MAT program. This theme was strongly tied to 
their knowledge and perceptions of criminal justice institution’s abstinent-based attitudes.  
Particularly, within ACJ, many noted the “substitute of one drug for another” mentality as being 
prevalent among the jail’s administration. The prevalence of these attitudes and perceptions has 
previously been documented among corrections officials as main drivers for establishing a drug-
free detoxification over MAT [91–93] . Correctional agency respondents within such study saw 
MAT as simply facilitating addiction, stating that it was “especially not appropriate for prisoners” 
[91]. Participants within the present study attributed this misperception to the lack of education 
among jail personnel [91]. This has also been cited in national surveys where over one third of 40 
correctional respondents—when asked about methadone—gave either no response or were unsure 
of benefits associated with methadone [94]. Although the majority of participants appeared to be 
well-versed in MAT, a significant amount of uncertainty and stigma about MAT in the CJS 
represents an opportunity to educate and raise awareness about the efficacy of MAT as a recovery 
tool. 
7.2 Exosystem 
 Policy All respondents but one directly highlighted and denounced Allegheny County 
Jail’s forced opioid withdrawal policy, even for detainees with Suboxone scripts or currently on 
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community-based methadone maintenance. And for community-based patients who had not been 
sentenced, but anticipated such sanctions in the near future, more than two health care respondents 
discussed how ACJ’s policy disrupted their patient’s treatment plan. However, according a clinical 
guide for “detoxification of chemically dependent inmates,” revised in 2018 by the Department of 
Justice, Federal Bureau of Prisons: 
“Inmates with short sentences, or with lengths of stay that are thirty days or less, 
generally should not be detoxified off benzodiazepines or barbiturates if these 
agents are currently medically indicated. However, opiate detoxification can be 
completed safely in less than two weeks. [However] Detoxification of inmates who 
have been using buprenorphine as maintenance therapy can be accomplished in an 
outpatient setting over several days.” [95] 
 Therefore, no apparent state or national regulations appear to be in place preventing forced 
opiate detoxification from occurring within any correctional institution, including detainees 
coming in on MAT. Previous studies have weighed heavily on this policy’s grave implications. A 
study conducted in Massachusetts and Rhode Island in 2012, found that nearly 50% of their study 
participants reported methadone detoxification as a deterrent to reengage in community treatment 
post-release [96]. These findings corroborated with Rich et al. study [97], citing that participants 
allowed to continue methadone during incarceration were more than twice as likely than the 
forced-detoxification group to reengage in community-based methadone treatment within a month 
of release. Other studies have cited to the subsequent aversion to MAT after being detained, 
indicating that they would rather withdraw from heroin than methadone [98]. In a more recent 
study conducted nationwide with 396 adults who had completed community treatment for OUD, 
posttreatment arrest was found to increase the likelihood of relapse [99]. 
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 Thus, forced correctional withdrawal policies in the CJS may seriously aggravate and deter 
a detainee in active recovery. Such policies not only disrupt the provision of evidence-based 
therapy, but violates eighth amendment protections against cruel and unusual punishment [8,100]. 
For example, denying inmates their insulin medication would be widely condemned as a 
constitutional violation. As such, limited access to MAT in the CJS warrants redressing this gap 
in care, that is both, health and human rights imperative. 
 Another policy limited MAT to expectant mothers within ACJ, helping to initiate MAT 
solely among this group, if not previously initiated in the community. This policy does fall within 
the rules and regulations of clinical guidelines of treating opiate-dependent pregnant women within 
the CJS [95]. However, contrary to SAMHSA’s clinical recommendation for postpartum opioid 
treatment [101] and systematic reviews citing the postpartum period as a time of increased risk for 
discontinuation of MAT [102], ACJ does taper the individual off of their MAT, postpartum.  
“The risk of return to substance use is high in this case, and the woman should be 
advised that the change should not be made without a compelling reason. Every 
effort should be made to avoid premature discontinuation of agonist therapy.” 
[101] 
Furthermore, Allegheny County Jail has been running a Vivitrol pilot program 
since fall of 2017, which can be seen, to some, as a step forward in advancing the harm 
reduction movement. However, many respondents alluded to Vivitrol as being the 
medical version of forced abstinence within the CJS. They attributed Vivitrol’s 
advancement in the CJS to the aggressive marketing tactics of Alkermes, the 
Massachusetts’s based pharmaceutical company that manufactures Vivitrol. Only neutral 
and negative remarks about Vivitrol were discussed by all participants, with the 
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exception of one abstinence-inclined provider. Participants, particularly those in the 
health care field who shared their patient experiences, perceived Vivitrol as a worse 
alternative than remaining abstinent from any medication. Because Vivitrol is a relatively 
new medication—only approved by the FDA in 2010—it has been understudied, 
specifically with criminal justice populations.  
 However, a few studies have investigated outcomes with CJS populations [103], examined 
attitudes associated with using extended-release naltrexone [104], and presented precipitated 
opioid withdrawal case studies [105]. In 2012, Coviello et al. [103] conducted a study with 
probation and drug court populations that found that participants who completed a minimum of 
six-monthly injections of Vivitrol, 6 months after their last injection, reflected fewer positive urine 
tests for opioids than those that fell short of the 6-month shots. Contrary to participant beliefs about 
Vivitrol, a qualitative study conducted in Ukraine found that focus group participants indicated 
interest in Vivitrol if supervised opioid withdrawal and psychological support was guaranteed 
[104]. Furthermore, although preliminary findings do suggest Vivitrol as a promising new practice, 
more research is needed among criminal justice populations to validate its treatment efficacy.  
Cost Although the cost-effectiveness of these medications, as they relate to 
reincarceration and opioid overdoses, are not well studied, literature does provide a basis for 
fiscal burdens imposed by arrests and incarceration [106]. In the state of Maryland, after 
adjusting costs for 2010, the estimated average cost of an arrest was estimated to be $4,568. This 
included arrest and investigation, booking, screening and pre-filing process, arraignment, pretrial 
hearings, and sentences. The cost of incarceration for one day was $89 [106]. Thus, the costs 
incurred by local government and associated departments appear to far exceed what maintaining 
someone on any form of MAT would cost. While other studies have shown that criminal justice 
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agencies run underfunded health care programs—largely due to the restrictions of Medicare and 
Medicaid for insuring anyone in U.S. jails and prisons [107]—a closer analysis at the financial 
feasibility of launching a jail-based MAT program is warranted. In 2018, NIDA provided a 
report of cost estimates associated with each FDA approved MAT [27]:  
• Methadone treatment, including medication and integrated psychosocial and medical 
support services (assumes daily visits):  $126.00 per week or $6,552.00 per year 
• Buprenorphine for a stable patient provided in a certified OTP, including medication and 
twice-weekly visits: $115.00 per week or $5,980.00 per year 
• Naltrexone provided in an OTP, including drug, drug administration, and related services: 
$1,176.50 per month or $14,112.00 per year [27] 
Of course, within correctional settings, as previously mentioned by participants, one 
would have to also account for staff time, contractor costs, transportation, facility licenses, and 
waivers. However, when comparing the base cost of these medications to those associated with a 
single case of arrest, policymakers could be more proactive in addressing these missed 
opportunities for revenue. Unfortunately, while an estimated $115 billion was spent on the 
opioid crisis nationally in 2017 (over $50 billion in Pennsylvania in 2016), a study found that in 
2013, only $2.8 billion was spent on SUD treatments in the United States [108].  
Security and diversion Finally, the most frequently cited logistical barrier to initiating a 
jail-based MAT program in Allegheny County was security concerns related to potential drug 
diversion, as well as other structural implications. This finding falls well in line with previous 
nationwide surveys that documented barriers regarding both methadone and buprenorphine 
prescribing policies in correctional facilities [91–94]. One study found that even if the medical 
director favored the provision of MAT, significant resistance would be met from the administrative 
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body, most commonly citing security concerns [91]. This also corroborates with one of the 
participant’s statements about medical policy being driven by security reasons. 
 Falling within the realm of security, criminal justice workers and abstinent-based 
providers cited the structural barrier of mixing abstinent populations with inmates on MAT. 
Some criminal justice respondents did not see a problem with this notion, but encountered 
resistance from other colleagues. Others mentioned the ready availability to spread such 
medications in ACJ’s treatment pod and disrupt formerly established treatment protocols. A 
previous study noted similar findings among wardens that stated, “diversion would represent a 
loss of control and the possibility that inmates may get “high” or even overdose” [93]. Wardens 
noted this as a liability as well as a “public health, medical and public safety concern” [93].  
7.3 Mesosystem 
 
Community Partnerships As in other studies [92,94], respondents also cited the 
insufficient provision of MAT from community service providers as being a barrier. This can be 
further supported by the National Survey of Substance Abuse Treatment Services that found that 
in 2016, only 36% of SUD treatment programs offered at least one MAT for treating OUD [109]. 
Because ACJ uses two community providers for transitioning their pregnant women, little is 
known about their outreach and collaboration efforts with other community providers in 
Allegheny County. Nonetheless, respondents did provide insights about the difficult processes 
associated with establishing those partnerships, especially when accounting for historical 
relationships held between abstinent-based community providers and jail, probation, and drug 
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court entities. Furthermore, regardless of whether participants felt that MAT was beneficial or 
detrimental, nearly all cited halfway homes as being predominantly abstinent-based in Allegheny 
County.   
These findings may be supported by a recent Allegheny County SUD provider survey 
(2016) that found that of 24 respondent organizations who participated, most (82%) offered 
MAT within their outpatient settings. Fifty percent offered Vivitrol or Oral Naltrexone, and 38% 
offered Suboxone. Halfway Houses within this survey had the lowest response count (3 or 13%) 
[86]. Although halfway houses are not obligated to provide medical care, many do provide 
substance abuse programming. Moreover, because a significant portion of returning citizens will 
pass through these transitional housing programs (many of which are abstinent-based) following 
jail release, it is imperative to ensure they are operating under evidence-based practice 
guidelines.  
 
Probation and drug courts The majority of participants also emphasized their grievances 
about judges and magistrates enforcing their abstinent-based ideology on returning citizens who 
would become subsequent patients of theirs. Participants believed that the autonomy of the 
defendant and appropriate medical treatment of OUD should take precedence over any judge’s 
bias and strong opinion against MATs. Such concerns have been previously shared in other studies 
[110,111]. In 2017, a study by the Physicians for Human Rights found that drug courts among 
three states were largely failing to provide medically informed treatment to those with OUD. In all 
cases observed within this study, nonmedical personnel assessed for OUD and some judges were 
identified as mandating treatment plans without consulting medical professionals [111]. Another 
study in New York State raised similar human rights concerns over drug court judges mandating 
defendants on stable methadone to be tapered off merely because they saw it is as the continuation 
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of addiction and deterrent to abstinence [110]. These misinformed, imposed regulations can stymie 
an opiate-dependent offender’s engagement with MAT, even if he or she believes it to be effective 
in their personal recovery path.  
Here, in Allegheny County, per an article published in the Pittsburgh Post-Gazette in 2018 
and according to Common Pleas Senior Judge G. Nauhaus, “Suboxone, methadone, is just another 
addiction.” The article goes on to state that with few exceptions, all drug court defendants in 
Allegheny County are required to remain abstinent and that others on medication have to agree to 
tapered off. Beyond a “Joint Position Statement on Medication-Assisted Treatment for Opioid Use 
Disorders in Allegheny County,” that did not include Allegheny County Drug Court, no other 
public information is available on the county’s drug court treatment orientation. Further, no stance 
on MAT is taken by the Administrative Office of Pennsylvania Courts (that oversee drug courts) 
or the Pennsylvania Association of Drug Court Professionals. This obviously presents a problem 
among 45 county drug courts in Pennsylvania that may enforce different rules.  
Stakeholders’ views on the lack of education on MAT among drug court officials also 
corroborated with another study as being a significant barrier. Matusow et al. [45]  found that 
among the 46 drug courts who indicated operating under a strict drug-free order, incorrect 
information on the efficacy of buprenorphine and methadone were more pronounced. Moreover, 
contrary to previous MAT studies ascertaining its efficacious medical qualities, only 5% of drug 
court officials agreed that MATs use is more effective than non-pharmacological treatments for 
OUD, compared to 32% in drug courts where MATs were readily available [45]. This, again, 
points to gaps in information about the medical efficacy of MAT among seemingly educated court 
judges. 
69 
Other concerns were raised about the enormous undertaking it would be to shift a drug-
free policy to pro-MAT when the county has about 25,000 on probation. The respondent elaborated 
on the potential for urine screenings to detect opiates in drug tests when on MAT. After reaching 
out to two criminal justice agents, one of which was not included in this study, it was relayed to 
me that the most common requested probation drug test used was the standard five-panel, which 
detects cocaine, marijuana, amphetamines, alcohol, PCP, and opiates. However, the agent clarified 
that even though methadone and buprenorphine have active opioid components, it would not result 
in a positive drug test. He stated, “some urine screens do list it as an opiate but most list Suboxone 
as Suboxone and methadone as methadone. Ours list it as Suboxone and methadone. Even in the 
case where it would come up positive for opioids, it would then be sent to a lab which with 99% 
certainty will list if it is buprenorphine or methadone.” Thus, the only way to detect methadone or 
buprenorphine is to test for it specifically, which does appear to be the common practice in 
Allegheny County. 
7.4 Facilitators and Recommendations 
According to Allegheny County Jail’s latest research report, “Changing Trends: An 
Analysis of the Allegheny County Jail Population,” more than 80% (13,237 of 16,436 booked in 
2011) of ACJ’s population were male, nearly 50% White, with the largest incarcerated age-group 
of 25-34 (34% or 9,686) [112]. Although these statistics were reported for 2011, Allegheny 
County’s most recent opioid-related death analysis identified similar markers for case fatalities in 
terms of general proportions. Further, the average length of stay for this year (2011) was 58 days, 
with a median of 10 days. Also, between 2006 and 2011, the most common ACJ booking was a 
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result of a new arrest, with 17% being transferred to another facility. Average length of stay for 
the transferred group was 86 days [112]. Moreover, as estimated by the criminal justice workers, 
somewhere between 60-70% of inmates pass through Allegheny County Jail with a SUD.  
A supplemental report in 2014 found that only 19% of ACJ’s population was charged with 
a violent crime, attributing the remaining 81% of bookings to drug, public order, and property 
offenses [113]. In light of these factors, there certainly exist opportunities to engage and/or 
continue an opiate-dependent offender’s treatment regimen prior to or during detainment. Due to 
the overrepresentation of low-profile crimes and SUD rates at ACJ, decriminalization approaches 
such as the Sequential Intercept Model could serve as the best practice for intervening and 
diverting opiate-dependent offenders. The Sequential Intercept Model (SIM) provides a theoretical 
framework for diverting misdemeanor and low-level felony defendants from incarceration, into 
needed substance use treatment [114,115] . Using public health principals of prevention, the model 
posits that opportunities for treatment exist at different intersect points that diverge from traditional 
criminal justice procedures [115]. To best outline policy prescriptions and recommendations as 
they relate to Allegheny County, the SIM will be adapted to the following intercept points: law 
enforcement engagement and pre-arrest (Intercept 1), post-arrest, initial detention, court and 
hearings (Intercept 2), jail and drug court (Intercept 3), community reentry from jail (Intercept 4), 
probation and parole (Intercept 5).  
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Figure 3. Criminal Justice Continuum Intercept Points 
 
7.4.1  Intercept 1: Law Enforcement Engagement 
While law enforcement officers are not trained to clinically assess and recommend 
treatment protocols, collaborating with community partners to conduct an overdose risk 
assessment and/or identify withdrawal symptoms associated with OUD, could bridge treatment 
gaps in the community. Building on this practice, a law enforcement-led initiative in Allegheny 
County could be established to divert opioid-dependent offenders to appropriate treatment service 
providers, prearrest. This would not only provide law enforcement with the opportunity to connect 
eligible offenders to treatment services, but avoid putting them under formal arrest procedures and 
stringent detox protocols.  
Since 2007, Pittsburgh officers have been trained under the Crisis Intervention Team (CIT) 
model to assess for mental illness and divert these individuals to Pittsburgh Mercy’s Central 
Recovery Center on the South Side, rather than incarcerate them. Similarly, in 2018, under a grant 
from the Pennsylvania Commission on Crime and Delinquency, a Post Overdose Response Team 
consisting of at least one police officer was formed. Under this model, PORT follows-up within a 
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week of an individual’s overdose event and assists with coordinating for treatment services. Thus, 
with appropriate training and community partnering, platforms are in place to help divert opiate-
dependent offenders to treatment. This community program approach would represent a more 
viable alternative to managing opiate-dependent offenders and minimizing associated risks with 
their arrest. These pre-booking diversion initiatives (e.g. Law Enforcement Assisted Diversion)—
specifically designed for substance use identification—have currently been advanced in other 
cities [110–112]. 
7.4.2  Intercept 2: Post-Arrest and Court 
As a general principal, during detainment period, eligible opiate-dependent offenders 
should be linked to community treatment as early as possible. Unfortunately, criminal court 
proceedings are underutilized events for establishing opioid overdose prevention protocols. In 
regard to arraignment procedures, the management and coordination of detainees and incarcerated 
opiate-dependent offenders should be of high priority. To address this, Allegheny County courts 
should collaborate with law enforcement officials, defense attorneys, prosecutors, and jails to 
modify booking procedures between time of arrest and arraignment to successfully assess and 
divert offenders at most risk for overdose. With appropriate consent, such legal protocols facilitate 
the streamlining of critical information about an offender’s treatment needs, treatment history, and 
recent treatment engagement (if currently on MAT).  
Additionally, in cases concerning brief detainment, jail policy should permit all detainees 
with active community-based MAT (e.g. methadone, Suboxone) involvement to continue their 
respective treatment regimens, regardless of facility transfer scenarios. In conjunction, because 
ACJ is a central booking agency, contracting a community partner to oversee opiate-dependent 
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detainees in the short-term (before their transition) could improve treatment coordination efforts 
and avoid forced detoxification protocols. 
7.4.3  Intercept 3: Jail and Drug Court 
During this pivotal intervention point, implementing a comprehensive overdose prevention 
program in tandem with MAT is critical. The Rhode Island Department of Corrections (RIDOC) 
was recently the first to implement such a program between its jail and prison populations. Many 
corrections officials from other states have since visited to learn more about their effective 
treatment model. Other national training efforts provided by the U.S. Department of Justice, 
Bureau of Justice Assistance, could also provide ACJ officials with a learning tool focused on 
implementing a continuum of care model to treat individuals with OUDs. Currently, use of a valid 
screening tool for OUD, traditional counseling, and naloxone education appears to be some of 
ACJ’s strongest programming components. Prevention Point Pittsburgh, a nonprofit organization 
dedicated to providing health empowerment services to injection drug users, has undertaken much 
of the overdose prevention education and training at ACJ. In 2014, over 400 individuals received 
this training at ACJ [86]. However, due to the frequent jail lockdown protocols in the last couple 
of years (2017-2018), it has become difficult to consistently provide these trainings. Additionally, 
providing monthly jail staff trainings on MAT and further establishing this educational component 
in the structure of the jail’s treatment pods, may bridge treatment gaps in holistic drug education 
among those incarcerated. Other similar advances could be made by creating an additional support 
network inclusive of medicated populations (e.g. Medication-Assisted Recovery Anonymous 
group). 
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As previously discussed, only a significantly small portion of ACJ’s jail population 
(expectant mothers) receive any form of MAT. However, due to this treatment orientation, 
mechanisms are currently in place to facilitate and expand MAT options to other populations who 
may be incarcerated beyond 30 days. First, Allegheny Health Network is currently contracted to 
provide all medical and psychiatric services and have vocalized their support for providing training 
and waivers for the provision of buprenorphine. Current doctors in ACJ provide pregnant women 
with Subutex. Additionally, because Suboxone and Subutex are known to be more divertible than 
methadone, providing an extended-release injection of Sublocade may eliminate security concerns 
associated with diversion. Secondly, an established partnership also appears to be in place with a 
local methadone clinic for all pregnant women who are clinically cleared to engage in treatment. 
Thus, ongoing treatment and transport protocols could be revised to expand treatment access to 
larger populations.  
In lieu of incarceration, other specialized diversion programs such as drug court, provide 
an organizational capacity to deliver timely evidence-based treatment to individuals living with 
OUD. Because Allegheny County drug court’s stance on MAT is unclear, educational trainings 
for judges and prosecutors that convey the implications of withdrawing someone from evidence-
based medication should be implemented. Thus, to avoid participant exclusion, drug court policy 
should be revised to permit opiate-dependent offenders to remain on or begin their maintenance 
medication during program. Furthermore, even though a Vivitrol pilot program has been in place 
since 2017 for all qualifying jail populations, a returning citizen’s recovery path should never be 
influenced or enforced by ill-informed correctional and judicial entities. 
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7.4.4  Intercept 4: Community Reentry from Jail 
The reentry period should facilitate the continuity of care between the jail and community 
behavioral health providers. Because the immediate post-release period is a critical period for all 
those involved in jail substance use treatment services, Allegheny County Jail policy should ensure 
proper referral and follow-up protocols for all those released with an OUD. In 2016, due to the 
alarming opioid-related overdose rates in Allegheny County, a “Risks and Opportunities for 
Intervention” report was released jointly by Department of Human Services and Department of 
Health. The report recommended evidence-based practices for Allegheny County Jail [86]:  
1.Universally assess ACJ inmates for opioid use and overdose risk. 
2.Provide naloxone to all inmates identified as using opiates and therefore at risk of 
overdose upon discharge from ACJ. 
3.Deliver evidence-based treatments (such as MAT) to ACJ inmates with an identified 
opiate-use disorder. 
4.Provide case management for those leaving ACJ and entering SUD treatment to improve 
rates of treatment, initiation and engagement. [86].  
While advances have been made in these recommendations, such as dissemination of 
naloxone and use of COWS for clinically assessing for OUD at jail entry—as evidenced by 
participants in this study—improvements in case management for linking returning citizens to 
community recovery services still need to be refined. Both, Allegheny Health Network and 
University of Pittsburgh Medical Center (UPMC) have established centers of excellence. Other 
community behavioral health providers (e.g. Tadiso Inc., Jade Wellness Center, Gateway Rehab, 
Cove Forge, Pittsburgh Mercy) that provide various forms of MAT could build or strengthen their 
relationships with ACJ. Establishing stronger provider partnerships within the jail could improve 
76 
treatment planning efforts, effectively, reducing the extra work load burden of criminal justice 
workers within ACJ. Continuing to collaborate with Pittsburgh Prevention Point, post-release, may 
also provide returning citizens with a stable community safety net. Furthermore, developing a 
comprehensive network of health providers, behavioral health providers, and public safety 
partnerships (e.g. Allegheny County Police, City of Pittsburgh, Allegheny County Emergency 
Services), could substantially bridge service gaps and mitigate opioid-related overdose events 
among returning citizens. 
7.4.5  Intercept 5: Probation and Parole 
Given Allegheny County’s high probation count, probation officers are in a unique position 
to supervise and support an offender’s community treatment rehabilitation. In collaboration with 
community providers, frequent contact events between community corrections personnel and 
probationers can mitigate lapses in treatment and reinforce the client’s recovery support network. 
Community research has found that factors influencing a returning citizen’s relapse cycle included 
(1) exposure to drug use in halfway houses or shelters, (2) loneliness and isolation, and (3) strained 
family or interpersonal relationships [116]. Therefore, service providers and probation officers can 
ensure returning citizens have adequate housing, employment, educational, and social support. 
Moreover, it is critical that community corrections personnel support the returning citizen’s 
treatment plan, including MAT as prescribed by appropriate treatment providers.  
Furthermore, it is important to recognize Allegheny County’s proactive efforts in 
mitigating the negative effects of the opioid epidemic in its community. In a Joint Position 
Statement on MAT for OUD, the Department of Human Services, Health Department, and other 
supportive organizations released a statement:  
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“Nobody should be penalized or taken off MAT because of involvement with the 
criminal justice system. The decision to initiate and sustain recovery using MAT, 
as well as the decision to discontinue using MAT, is a medical decision made by 
an individual, a clinical team and a doctor. Discontinuation requires careful 
planning to ensure adequate treatment and ensure adequate treatment with a focus 
on recovery, overdose prevention and risk reduction. Criminal justice professionals 
are entitled to information about the individual’s progress; however, it is never 
acceptable to order discontinuation of MAT as a condition of court supervision. 
Furthermore, federal funding for drug courts should be contingent upon the drug 
court utilizing MAT when clinically appropriate” [113]. 
In addition, “treatment providers that do not offer MAT as an option cannot be considered 
evidence-based providers” [113]. Because a substantial amount of concerns was raised among this 
study’s participants about halfway homes deterring evidence-based practice of MAT, community 
efforts should target and edify recovery housing programs of the benefits of MAT as a sustainable 
recovery tool. Buy-in from managers, counselors, and medical staff of such programs is imperative 
for effective interventions among opiate-dependent returning citizens. Advocacy suggestions are 
available on the website of American Association for the Treatment of Opioid Dependence 
(http://www.aatod.org). Additionally, the Bureau of Justice Assistance in the Unites States 
Department of Justice has also published an important training tool “Residential Substance Abuse 
Treatment: Medication Assisted Treatment for Offender Populations”. This comprehensive 
training tool provides guidance and in-depth recommendations on how proceed forward with 
initiating use of MAT for opioid addiction [114]. 
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7.5 Limitations and Strengths 
A major limitation of this study is that the sample size was small. Although a combination 
of purposive and snowball sampling was used, time constraints limited our ability provide a more 
diverse sample of participants. However, the sample size was sufficient for developing thematic 
constructs and guiding the related research questions of the study. Additionally, the design of the 
survey and semistructured interviews may have influenced response selection bias, especially 
among participants well-versed in the medical practice of MAT. Thus, the local context of 
perceptions and information shared by participants in this convenience sample may not be 
generalizable or representative of their agency. To a certain degree, saturation was reached with 
the data, however, because the sample size did not capture the majority of representative agencies 
in the county, we were careful not to rely solely on information provided by these respondents. 
Furthermore, our study is the first to provide an in-depth perspective of stakeholders at 
different levels of influence within a local community currently being impacted by the national 
opioid epidemic. The qualitative nature of this study allows for participants’ own words to 
illustrate challenges encountered as a result of local public policy. The study further integrates a 
community-based approach, offering policy makers and other relevant stakeholders’ insightful 
considerations for improving public health practices, especially within Allegheny County Jail.   
79 
8.0 Conclusion 
The current study highlights the need to address treatment gaps associated with health care 
policy among criminal justice institutions. Further, jail and community efforts to improve the 
delivery of MAT should be holistic in reducing the harmful effects of addiction with such 
vulnerable populations. In doing so, health literacy, compassion, and understanding should be 
increased and disseminated across the different systems (i.e., policy makers, general public, 
frontline service delivery professionals, criminal justice officials) while combatting negative and 
misinformed beliefs that perpetuate stigma.  
Furthermore, given that jails have much higher turnover rates and shorter periods of 
incarceration than prisons, MAT patients who are detained would significantly benefit from the 
continuity of their treatment. In the absence of such evidence-based practices, including effective 
linkage to community recovery services, returning opiate-dependent citizens run a greater risk in 
harming themselves and the communities in which they return to. Therefore, preventative 
collaboration and revision in policy could substantially mitigate risks associated with recidivism, 
opioid relapse, and overdose in the immediate post-release period. 
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Appendix A Interview Guide 
Interview Guide 
 
• To your knowledge, what is the percentage of the jail’s population with opioid or alcohol 
dependence? 
 
• What are the populations provided with MAT (e.g. men/women, pregnant women, 
individuals infected with HIV)? 
o What is ACJ’s treatment practice in the event that an individual is admitted 
experiencing opiate withdrawal? 
o What about for all individuals admitted who had been receiving community-based 
MAT prior to being detained? 
 
• How does ACJ screen, assess, and triage individuals who may be potentially diagnosed 
with Opioid Use Disorder? 
o What services or programs are available to inmates who have a substance use 
disorder, specifically OUD? 
o How do you educate inmates about the risk of overdose and MAT practices? 
o How are medical staff, clinical staff, or other health care personnel trained to 
recognize and treat SUDs, withdrawal, and/or to utilize MAT?  
 
• What specific Medication is currently available at ACJ? 
o How does ACJ administer/fund each specific MAT (e.g. contract personnel, own 
license, coordinate with outside clinics)? 
o What is the protocol for which type is dispensed to individual? 
o How involved is the individual in his treatment process and options? 
 
• Following completion of treatment or when individual is being released (receiving 
MAT), what is the referral system ACJ use to connect inmates to community-based 
providers to maintain continuation of treatment? 
o Does ACJ provide assistance with enrolling inmates in health insurance plans 
(e.g. Medicaid) prior to release? 
o On release, do you dispense a limited supply of medications to inmate? 
 If so? How is coverage for medications following release coordinated? 
o What about for those under community correctional supervision, such as drug 
court clients, what is the process for connecting them to a community service 
provider that provides MAT?  
o What community reentry or aftercare services are provided, especially for those 
coming out of the ACJ’s substance use services unit? 
 
• Does Allegheny County Jail have any intention of applying for a SAMHSA certification 
to become a prison-based OTP (Opioid Treatment Program)? 
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o Are there any plans to partner with a community OTP to open a medication unit 
in the prison while operating within the appropriate regulatory structure? 
o Likelihood that ACJ would expand MAT in the next 2 years to all jail 
populations? 
 
• In your opinion, is it possible to expand use of MAT for opiate and alcohol addiction? 
o Do the forms of MAT currently being implement benefit opiate-dependent 
inmates?  
o How would user behavior change if all forms of MAT were initiated at ACJ to all 
jail populations? 
 
Participants Outside of ACJ 
 
• What’s the biggest challenge [Line of Work/Service] face with regard to the opioid 
epidemic? 
• In your line of work, what is the general sense [Line of Work/Service] get about 
Medication-Assisted Treatment or other harm reduction strategies? Are they informed or 
onboard with these treatment philosophies? 
• What’re the biggest barriers [Line of Work/Service] face with regard to preventing 
opioid-related overdoses among recently released inmates? 
• What role do you see Allegheny County Jail playing in reducing the number of overdoses 
and/or substance abuse that occur within the county, specifically for those who are 
released eliciting opioid-dependent symptoms? 
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Appendix B Survey: Practices, Perceptions, and Barriers that Influence Allegheny County 
Jail’s MAT Use 
Practices, Perceptions, and Barriers that Influence Allegheny County Jail’s MAT Use 
Using a Likert-type scale where a rating of 1 indicates the factor is “Not important” and a 
rating of 5 indicates the factor is “Very important,” ask respondent to rate the following factors, 
asking open-ended questions regarding all factors rated 4 or 5: 
1. Negative Perception of MAT as a Substitute Drug
2. Jail, Probation, and Drug Courts Favor Drug-Free Treatment
3. Inadequate Info at Jail about MAT
4. Uninformed of Clinical Effectiveness for CJ Populations
5. Cost and Reimbursement Issues
6. Logistical Obstacles
7. Inconsistent with Jail's Treatment Philosophy
8. Liability Concerns
9. Limited Partnerships with CSPs
10. Physical Health Focus Over SUD Treatment
11. Administrative Opposition
12. Clinical Staff Object to MAT
13. Human Resource Limitation
14. Lack of Qualified Medical Staffing
15. Community Service Providers offer MAT
16. State/Local Regulations Prohibit Prescribing MAT
17. OUD is an Uncommon Problem in Jail
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